<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T03:23:13Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:8174157" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:8174157</identifier>
        <datestamp>2021-06-11</datestamp>
        <setSpec>jaha</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" article-type="research-article">
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">J Am Heart Assoc</journal-id>
              <journal-id journal-id-type="iso-abbrev">J Am Heart Assoc</journal-id>
              <journal-id journal-id-type="doi">10.1002/(ISSN)2047-9980</journal-id>
              <journal-id journal-id-type="publisher-id">JAH3</journal-id>
              <journal-id journal-id-type="hwp">ahaoa</journal-id>
              <journal-title-group>
                <journal-title>Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease</journal-title>
              </journal-title-group>
              <issn pub-type="epub">2047-9980</issn>
              <publisher>
                <publisher-name>John Wiley and Sons Inc.</publisher-name>
                <publisher-loc>Hoboken</publisher-loc>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC8174157</article-id>
              <article-id pub-id-type="pmcid">PMC8174157</article-id>
              <article-id pub-id-type="pmc-uid">8174157</article-id>
              <article-id pub-id-type="pmid">33840228</article-id>
              <article-id pub-id-type="pmid">33840228</article-id>
              <article-id pub-id-type="doi">10.1161/JAHA.120.017401</article-id>
              <article-id pub-id-type="publisher-id">JAH35911</article-id>
              <article-categories>
                <subj-group subj-group-type="overline">
                  <subject>Original Research</subject>
                </subj-group>
                <subj-group subj-group-type="heading">
                  <subject>Original Research</subject>
                  <subj-group subj-group-type="heading">
                    <subject>Preventive Cardiology</subject>
                  </subj-group>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Plasma Omega‐3 Fatty Acids and the Risk of Cardiovascular Events in Patients After an Acute Coronary Syndrome in MERLIN‐TIMI 36</article-title>
                <alt-title alt-title-type="right-running-head">n3‐PUFA in Patients After ACS</alt-title>
                <alt-title alt-title-type="left-running-head">Zelniker et al</alt-title>
              </title-group>
              <contrib-group>
                <contrib id="jah35911-cr-0001" contrib-type="author">
                  <name>
                    <surname>Zelniker</surname>
                    <given-names>Thomas A.</given-names>
                  </name>
                  <degrees>MD, MSc</degrees>
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-6444-8598</contrib-id>
                  <xref ref-type="aff" rid="jah35911-aff-0001">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib id="jah35911-cr-0002" contrib-type="author">
                  <name>
                    <surname>Morrow</surname>
                    <given-names>David A.</given-names>
                  </name>
                  <degrees>MD, MPH</degrees>
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-9589-5382</contrib-id>
                  <xref ref-type="aff" rid="jah35911-aff-0002">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib id="jah35911-cr-0003" contrib-type="author">
                  <name>
                    <surname>Scirica</surname>
                    <given-names>Benjamin M.</given-names>
                  </name>
                  <degrees>MD, MPH</degrees>
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-7093-7048</contrib-id>
                  <xref ref-type="aff" rid="jah35911-aff-0002">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib id="jah35911-cr-0004" contrib-type="author">
                  <name>
                    <surname>Furtado</surname>
                    <given-names>Jeremy D.</given-names>
                  </name>
                  <degrees>ScD</degrees>
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-5258-1869</contrib-id>
                  <xref ref-type="aff" rid="jah35911-aff-0003">
                    <sup>3</sup>
                  </xref>
                </contrib>
                <contrib id="jah35911-cr-0005" contrib-type="author">
                  <name>
                    <surname>Guo</surname>
                    <given-names>Jianping</given-names>
                  </name>
                  <degrees>MAS</degrees>
                  <xref ref-type="aff" rid="jah35911-aff-0002">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib id="jah35911-cr-0006" contrib-type="author">
                  <name>
                    <surname>Mozaffarian</surname>
                    <given-names>Dariush</given-names>
                  </name>
                  <degrees>MD, DrPH</degrees>
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-7958-9492</contrib-id>
                  <xref ref-type="aff" rid="jah35911-aff-0004">
                    <sup>4</sup>
                  </xref>
                </contrib>
                <contrib id="jah35911-cr-0007" contrib-type="author">
                  <name>
                    <surname>Sabatine</surname>
                    <given-names>Marc S.</given-names>
                  </name>
                  <degrees>MD, MPH</degrees>
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-0691-3359</contrib-id>
                  <xref ref-type="aff" rid="jah35911-aff-0002">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib id="jah35911-cr-0008" contrib-type="author" corresp="yes">
                  <name>
                    <surname>O’Donoghue</surname>
                    <given-names>Michelle L.</given-names>
                  </name>
                  <degrees>MD, MPH</degrees>
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-8663-0067</contrib-id>
                  <xref ref-type="aff" rid="jah35911-aff-0002">
                    <sup>2</sup>
                  </xref>
                  <address>
                    <email>modonoghue@bwh.harvard.edu</email>
                  </address>
                </contrib>
              </contrib-group>
              <aff id="jah35911-aff-0001">
                <label>
                  <sup>1</sup>
                </label>
                <named-content content-type="organisation-division">Division of Cardiology</named-content>
                <institution>Vienna General Hospital</institution>
                <institution>Medical University of Vienna</institution>
                <country country="AT">Austria</country>
              </aff>
              <aff id="jah35911-aff-0002">
                <label>
                  <sup>2</sup>
                </label>
                <named-content content-type="organisation-division">TIMI Study Group</named-content>
                <named-content content-type="organisation-division">Division of Cardiovascular Medicine</named-content>
                <institution>Brigham and Women's Hospital and Harvard Medical School</institution>
                <city>Boston</city>
                <named-content content-type="country-part">MA</named-content>
              </aff>
              <aff id="jah35911-aff-0003">
                <label>
                  <sup>3</sup>
                </label>
                <named-content content-type="organisation-division">Department of Nutrition</named-content>
                <institution>Harvard T. H. Chan School of Public Health</institution>
                <city>Boston</city>
                <named-content content-type="country-part">MA</named-content>
              </aff>
              <aff id="jah35911-aff-0004">
                <label>
                  <sup>4</sup>
                </label>
                <named-content content-type="organisation-division">Friedman School of Nutrition Science and Policy</named-content>
                <institution>Tufts University</institution>
                <city>Boston</city>
                <named-content content-type="country-part">MA</named-content>
              </aff>
              <author-notes>
                <corresp id="correspondenceTo"><label>*</label>
Correspondence to: Michelle L. O'Donoghue, MD, MPH, TIMI Study Office, 60 Fenwood Rd., Suite 7022‐7024W, Boston, MA 02115. E‐mail: <email>modonoghue@bwh.harvard.edu</email><break/></corresp>
              </author-notes>
              <pub-date pub-type="epub">
                <day>12</day>
                <month>4</month>
                <year>2021</year>
              </pub-date>
              <pub-date pub-type="collection">
                <day>20</day>
                <month>4</month>
                <year>2021</year>
              </pub-date>
              <volume>10</volume>
              <issue>8</issue>
              <issue-id pub-id-type="doi">10.1002/jah3.v10.8</issue-id>
              <elocation-id>e017401</elocation-id>
              <history>
                <date date-type="received">
                  <day>06</day>
                  <month>5</month>
                  <year>2020</year>
                </date>
                <date date-type="accepted">
                  <day>17</day>
                  <month>12</month>
                  <year>2020</year>
                </date>
              </history>
              <permissions>
                <!--<copyright-statement content-type="issue-copyright">Copyright &#x000a9; 2021 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley Blackwell<copyright-statement>-->
                <copyright-statement content-type="article-copyright">© 2021 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley.</copyright-statement>
                <license>
                  <ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref>
                  <license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link> License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.</license-p>
                </license>
              </permissions>
              <self-uri content-type="pdf" xlink:href="file:JAH3-10-e017401.pdf"/>
              <abstract id="jah35911-abs-0001">
                <sec id="jah35911-sec-0001">
                  <title>Background</title>
                  <p>Plasma omega‐3 polyunsaturated fatty acids (ω3‐PUFAs) have been shown to be inversely correlated with the risk of cardiovascular death in primary prevention. The risk relationship in the setting of an acute coronary syndrome is less well established.</p>
                </sec>
                <sec id="jah35911-sec-0002">
                  <title>Methods and Results</title>
                  <p>Baseline plasma ω3‐PUFA composition (α‐linolenic acid, eicosapentaenoic acid, docosapentaenoic acid, and docosahexaenoic acid) was assessed through gas chromatography with flame ionization detection in a case‐cohort study involving 203 patients with cardiovascular death, 325 with myocardial infarction, 271 with ventricular tachycardia, and 161 with atrial fibrillation, and a random sample of 1612 event‐free subjects as controls from MERLIN‐TIMI 36 (Metabolic Efficiency With Ranolazine for Less Ischemia in Non–ST‐Elevation‐Acute Coronary Syndrome–Thrombolysis in Myocardial Infarction 36), a trial of patients hospitalized with non–ST‐segment–elevation ‐acute coronary syndrome. After inverse‐probability‐weighted multivariable adjustment including all traditional risk factors, a higher relative proportion of long‐chain ω3‐PUFAs (eicosapentaenoic acid, docosapentaenoic acid, docosahexaenoic acid) were associated with 18% lower odds of cardiovascular death (adjusted [adj] odds ratio [OR] per 1 SD, 0.82; 95% CI, 0.68–0.98) that was primarily driven by 27% lower odds of sudden cardiac death (adj OR per 1 SD, 0.73; 95% CI, 0.55–0.97). Long‐chain ω3‐PUFA levels in the top quartile were associated with 51% lower odds of cardiovascular death (adj OR 0.49; 95% CI, 0.27–0.86) and 63% lower odds of sudden cardiac death (adj OR, 0.37; 95% CI, 0.16–0.56). An attenuated relationship was seen for α‐linolenic acid and subsequent odds of cardiovascular (adj OR, 0.92; 95% CI, 0.74–1.14) and sudden cardiac death (adj OR, 0.91; 95% CI, 0.67–1.25). No significant relationship was observed between any ω3‐PUFAs and the odds of cardiovascular death unrelated to sudden cardiac death, myocardial infarction, atrial fibrillation, or early post‐acute coronary syndrome ventricular tachycardia.</p>
                </sec>
                <sec id="jah35911-sec-0003">
                  <title>Conclusions</title>
                  <p>In patients after non–ST‐segment–elevation‐acute coronary syndrome, plasma long‐chain ω3‐PUFAs are inversely associated with lower odds of sudden cardiac death, independent of traditional risk factors and lipids.</p>
                </sec>
                <sec id="jah35911-sec-0004">
                  <title>Registration</title>
                  <p>URL: <ext-link ext-link-type="uri" xlink:href="https://www.clinicaltrials.gov">https://www.clinicaltrials.gov</ext-link>. Unique identifier: NCT00099788.</p>
                </sec>
              </abstract>
              <kwd-group>
                <kwd id="jah35911-kwd-0001">acute coronary syndrome</kwd>
                <kwd id="jah35911-kwd-0002">omega‐3 polyunsaturated fatty acids</kwd>
                <kwd id="jah35911-kwd-0003">sudden cardiac death</kwd>
              </kwd-group>
              <kwd-group kwd-group-type="subject-categories">
                <title>Subject Categories</title>
                <kwd>Secondary Prevention</kwd>
                <kwd>Risk Factors</kwd>
                <kwd>Acute Coronary Syndromes</kwd>
              </kwd-group>
              <funding-group>
                <award-group id="funding-0001">
                  <funding-source>NIH National Center for Advancing Translational Sciences (NCATS) of the National Institutes of Health</funding-source>
                </award-group>
                <award-group id="funding-0002">
                  <funding-source>
                    <institution-wrap>
                      <institution>NHLBI </institution>
                      <institution-id institution-id-type="open-funder-registry">10.13039/100000050</institution-id>
                    </institution-wrap>
                  </funding-source>
                  <award-id>R01HL098280</award-id>
                </award-group>
                <award-group id="funding-0003">
                  <funding-source>
                    <institution-wrap>
                      <institution>Deutsche Forschungsgemeinschaft </institution>
                      <institution-id institution-id-type="open-funder-registry">10.13039/501100001659</institution-id>
                    </institution-wrap>
                  </funding-source>
                  <award-id>ZE 1109/1‐1</award-id>
                </award-group>
                <award-group id="funding-0004">
                  <funding-source>CV Therapeutics</funding-source>
                </award-group>
              </funding-group>
              <counts>
                <fig-count count="4"/>
                <table-count count="1"/>
                <page-count count="9"/>
                <word-count count="6499"/>
              </counts>
              <custom-meta-group>
                <custom-meta>
                  <meta-name>source-schema-version-number</meta-name>
                  <meta-value>2.0</meta-value>
                </custom-meta>
                <custom-meta>
                  <meta-name>cover-date</meta-name>
                  <meta-value>April 20, 2021</meta-value>
                </custom-meta>
                <custom-meta>
                  <meta-name>details-of-publishers-convertor</meta-name>
                  <meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.0.2 mode:remove_FC converted:19.04.2021</meta-value>
                </custom-meta>
              </custom-meta-group>
            </article-meta>
            <notes>
              <p content-type="self-citation">
                <mixed-citation publication-type="journal" id="jah35911-cit-1001">(<source xml:lang="en">J Am Heart Assoc</source>.<year>2021</year>;<volume>10</volume>:<elocation-id>e017401</elocation-id>. DOI: <pub-id pub-id-type="doi">10.1161/JAHA.120.017401</pub-id>.)<pub-id pub-id-type="pmid">33840228</pub-id></mixed-citation>
              </p>
              <fn-group id="jah35911-ntgp-0001">
                <fn id="jah35911-note-0001">
                  <p>Supplementary Material for this article is available at <ext-link ext-link-type="uri" xlink:href="https://www.ahajournals.org/doi/suppl/10.1161/JAHA.120.017401">https://www.ahajournals.org/doi/suppl/10.1161/JAHA.120.017401</ext-link>
</p>
                </fn>
                <fn id="jah35911-note-0002">
                  <p>For Sources of Funding and Disclosures, see page 8.</p>
                </fn>
              </fn-group>
            </notes>
          </front>
          <body id="jah35911-body-0001">
            <def-list list-content="abbreviations" id="jah35911-lp-0001">
              <title>Nonstandard Abbreviations and Acronyms</title>
              <def-item>
                <term>ALA</term>
                <def>
                  <p>α‐linolenic acid</p>
                </def>
              </def-item>
              <def-item>
                <term>DHA</term>
                <def>
                  <p>docosahexaenoic acid</p>
                </def>
              </def-item>
              <def-item>
                <term>DPA</term>
                <def>
                  <p>docosapentaenoic acid</p>
                </def>
              </def-item>
              <def-item>
                <term>EPA</term>
                <def>
                  <p>eicosapentaenoic acid</p>
                </def>
              </def-item>
              <def-item>
                <term>ω3‐PUFA</term>
                <def>
                  <p>omega‐3 polyunsaturated fatty acid</p>
                </def>
              </def-item>
            </def-list>
            <p>
              <boxed-text position="anchor" content-type="box" id="jah35911-blkfxd-0001" orientation="portrait">
                <sec id="jah35911-sec-0006">
                  <title>Clinical Perspective</title>
                  <sec id="jah35911-sec-0007">
                    <title>What Is New?</title>
                    <p>
                      <list list-type="bullet" id="jah35911-list-0001">
                        <list-item>
                          <p>In patients with non–ST‐segment–elevation–acute coronary syndromes, a higher relative proportion of long‐chain omega‐3 polyunsaturated fatty acid (ω3‐PUFAs) content in plasma is associated with lower odds of cardiovascular and sudden cardiac death, independent of traditional risk factors and lipids.</p>
                        </list-item>
                        <list-item>
                          <p>Although directional consistency was seen across the ω3 subtypes, the magnitude of the effect appeared to be greatest for the long‐chain marine‐based ω3‐PUFAs including docosahexaenoic acid, docosapentaenoic acid, and eicosapentaenoic acid.</p>
                        </list-item>
                      </list>
                    </p>
                  </sec>
                  <sec id="jah35911-sec-0008">
                    <title>What Are the Clinical Implications?</title>
                    <p>
                      <list list-type="bullet" id="jah35911-list-0002">
                        <list-item>
                          <p>These data lend support to the theory that certain types of ω3 supplementation may reduce the risk of adverse cardiovascular outcomes in higher‐risk populations.</p>
                        </list-item>
                      </list>
                    </p>
                  </sec>
                </sec>
              </boxed-text>
            </p>
            <sec sec-type="opening-section" id="jah35911-sec-0009">
              <p>Omega‐3 polyunsaturated fatty acids (ω3‐PUFA) are incorporated into cellular membranes where they are believed to modulate cellular signaling, gene expression, and membrane protein function.<xref rid="jah35911-bib-0001" ref-type="ref"><sup>1</sup></xref>, <xref rid="jah35911-bib-0002" ref-type="ref"><sup>2</sup></xref> α‐linolenic acid (ALA) is obtained through plant‐derived dietary intake, whereas the long‐chain ω3‐PUFAs including eicosapentaenoic acid (EPA), docosapentaenoic acid (DPA), and docosahexaenoic acid (DHA) are primarily obtained from marine sources. In meta‐analyses of randomized controlled trials, ω3‐PUFA supplementation has been shown to lower serum triglycerides, lower blood pressure, lower heart rate, and improve endothelial function.<xref rid="jah35911-bib-0001" ref-type="ref"><sup>1</sup></xref>, <xref rid="jah35911-bib-0002" ref-type="ref"><sup>2</sup></xref> Based on experimental studies, numerous beneficial roles for ω3‐PUFAs have been postulated including a reduction in atherogenesis, collagen deposition, dysrhythmias, inflammation, platelet aggregation and improved plaque stabilization, and vasodilation.<xref rid="jah35911-bib-0001" ref-type="ref"><sup>1</sup></xref>, <xref rid="jah35911-bib-0002" ref-type="ref"><sup>2</sup></xref> However, clinical outcome trials of exogenous ω3‐PUFA supplementation have yielded mixed results; therefore, the physiological effects as well as the magnitude and dose‐response of their effects remain controversial.<xref rid="jah35911-bib-0003" ref-type="ref"><sup>3</sup></xref>, <xref rid="jah35911-bib-0004" ref-type="ref"><sup>4</sup></xref>, <xref rid="jah35911-bib-0005" ref-type="ref"><sup>5</sup></xref>, <xref rid="jah35911-bib-0006" ref-type="ref"><sup>6</sup></xref>, <xref rid="jah35911-bib-0007" ref-type="ref"><sup>7</sup></xref>, <xref rid="jah35911-bib-0008" ref-type="ref"><sup>8</sup></xref>
</p>
              <p>In the absence of supplementation, ω3‐PUFA content has been shown to be inversely correlated with risk of cardiovascular and sudden cardiac death, but less strongly associated with risk of myocardial infarction or stroke.<xref rid="jah35911-bib-0009" ref-type="ref"><sup>9</sup></xref>, <xref rid="jah35911-bib-0010" ref-type="ref"><sup>10</sup></xref> As such, it has been hypothesized that ω3‐PUFA supplementation could confer beneficial effects following acute coronary syndrome (ACS), when patients are at higher risk of arrhythmic events, due to their favorable effects on membrane stabilization.<xref rid="jah35911-bib-0011" ref-type="ref"><sup>11</sup></xref> To that end, in the only large clinical trial of patients with a recent myocardial infarction, ω3‐PUFA supplementation reduced the risk of cardiovascular death by 30%, primarily driven by a 45% reduction in the risk of sudden death.<xref rid="jah35911-bib-0008" ref-type="ref"><sup>8</sup></xref> However, the trial was open label, and additional studies in this high‐risk population with recent ACS have not been performed.</p>
              <p>Thus, patients with recent ACS remain a vulnerable population at increased risk for recurrent cardiovascular events and sudden cardiac death, in whom ω3‐PUFA could hypothetically be protective. To better understand their physiological effects, we examined the association between ω3‐PUFA content and the risk of cardiovascular events, including arrhythmic events, in a large clinical trial population hospitalized with ACS.</p>
            </sec>
            <sec sec-type="materials-and-methods" id="jah35911-sec-0010">
              <title>Methods</title>
              <p>The data, analytic methods, and study materials will not be made available to other researchers for purposes of reproducing the results or replicating the procedure. However, we encourage parties interested in collaboration and data sharing to contact the corresponding author directly for further discussions.</p>
              <sec id="jah35911-sec-0011">
                <title>Patient Population</title>
                <p>The design and the primary results of the MERLIN‐TIMI 36 (Metabolic Efficiency With Ranolazine for Less Ischemia in Non–ST‐Elevation Acute Coronary Syndrome–Thrombolysis in Myocardial Infarction 36) trial have been published previously.<xref rid="jah35911-bib-0012" ref-type="ref"><sup>12</sup></xref>, <xref rid="jah35911-bib-0013" ref-type="ref"><sup>13</sup></xref> In brief, the MERLIN‐TIMI 36 trial was a randomized, controlled, double‐blinded trial that compared ranolazine with placebo in 6560 patients hospitalized with a non–ST‐segment–elevation ACS within 48 hours of symptoms onset. Patients eligible for enrollment had at least 10 minutes of ischemic symptoms at rest and presented with one of the following additional risk indicators: elevated biomarkers of myonecrosis, ST depression ≥0.1 mV, history of diabetes mellitus, or an intermediate‐to‐high (≥3) Thrombolysis in Myocardial Infarction (TIMI) Risk Score. Patients were excluded if they had end‐stage renal disease requiring dialysis, cardiogenic shock, or a life expectancy of &lt;1 year. The protocol, including the biomarker and Holter substudies, was approved by institutional review boards, and written consent was obtained from all participating patients.</p>
              </sec>
              <sec id="jah35911-sec-0012">
                <title>Study Design and Biomarker Testing</title>
                <p>At randomization (median 24 hours from symptom onset), a plasma sample was drawn and stored at −20°C until shipped to the TIMI Clinical Trials Laboratory (Boston, MA), where it was maintained at −80°C or colder. Samples were recorded as fasting or nonfasting by sites.</p>
                <p>The present metabolomics array study was designed as a case‐cohort study to leverage the control population to examine &gt;1 outcome of interest.<xref rid="jah35911-bib-0014" ref-type="ref"><sup>14</sup></xref> The study population included a total of 2407 patients (1167 randomized to ranolazine and 1240 randomized to placebo). Overall, 203 subjects with cardiovascular death (including 86 sudden cardiac deaths), 325 patients with myocardial infarction, 271 with ventricular tachycardia, and 161 with atrial fibrillation events were selected as cases in addition to a random sample of 1612 event‐free subjects serving as controls. Plasma samples were collected at randomization, and the composition of fatty acids were assessed through gas chromatography with flame ionization detection in the Nutritional Biomarker Laboratory of the Department of Nutrition at the Harvard T. H. Chan School of Public Health using previously published methodology.<xref rid="jah35911-bib-0015" ref-type="ref"><sup>15</sup></xref> Herein, we focus on the baseline plasma ω3‐PUFA composition including ALA and the 3 long‐chain marine‐based ω3‐PUFAs, EPA, DPA, and DHA.</p>
              </sec>
              <sec id="jah35911-sec-0013">
                <title>End Points</title>
                <p>Mode of death and cardiovascular outcomes of interest were adjudicated by an independent and blinded clinical events committee. As part of the study protocol, all patients in the MERLIN‐TIMI 36 trial were to wear a Holter monitor (Lifecard CF; DelMar Reynolds/Spacelabs) starting at randomization for a period of 7 days, including after hospital discharge.<xref rid="jah35911-bib-0012" ref-type="ref"><sup>12</sup></xref>, <xref rid="jah35911-bib-0016" ref-type="ref"><sup>16</sup></xref> Analysts and cardiologists blinded to treatment assignment and outcomes determined the presence and type of arrhythmia in the TIMI ECG Core Laboratory. As described previously,<xref rid="jah35911-bib-0017" ref-type="ref"><sup>17</sup></xref> clinical atrial fibrillation events were identified through adverse‐event reporting throughout the duration of study follow‐up.</p>
              </sec>
              <sec id="jah35911-sec-0014">
                <title>Statistical Analysis</title>
                <p>The ω3‐PUFA composition including ALA, EPA, DPA, and DHA are expressed as the percentage of the total fatty acid content by weight. The baseline characteristics were compared by quartiles of ω3 fatty acid using the Kruskal‐Wallis test for continuous variables and the χ<sup>2</sup> test for categorical variables. Correlations between ω3 fatty acid subtypes were examined using Spearman correlation coefficients.</p>
                <p>ω3 fatty acids were modeled both as continuous variables as well as categorized using quartiles. Adjusted odds ratios were determined using logistic regression models that included the following variables: age, sex, estimated glomerular filtration rate (estimated with the Modification of Diet in Renal Disease formula), hypertension, prior myocardial infarction, heart failure, diabetes mellitus, smoking, statin use, baseline low‐density lipoprotein cholesterol, high‐density lipoprotein cholesterol, triglycerides, body mass index, race, region, index diagnosis, and randomized treatment arm. The logistic regression models included a weighted likelihood approach using inverse probability weighting using design weight (for cases weight=1, controls weight=1 over the sampling fraction of noncases) to account for oversampling of cases and adjusted variance using robust standard error estimation/sandwich estimator for consistent estimation of variance in the presence of upweighting of controls.<xref rid="jah35911-bib-0018" ref-type="ref"><sup>18</sup></xref> Sensitivity analyses were performed in subjects in whom fasting plasma samples were available (n=1384, 57.5%). Subgroup analyses were conducted for the outcome of sudden cardiac death stratified by low‐density lipoprotein cholesterol (≤ or &gt;130 mg/dL), triglycerides (&lt; or ≥150 mg/dL), TIMI Risk Score (≤ or &gt;3), and high‐sensitivity C‐reactive protein (≤ or &gt;5 mg/L). Tests for heterogeneity were determined by including an interaction term in the adjusted models. Splines were modeled by restricted cubic splines with 3 knots at the 10th, 50th, and 90th percentile based on Frank Harrell's SAS macro.</p>
                <p>All analyses were performed using SAS (version 9.4; SAS Institute). Given the exploratory nature of the analysis, a <italic>P</italic> value (2‐tailed) &lt;0.05 was considered statistically significant. The authors had full access to and take full responsibility for the integrity of the data. All statistical analyses were performed at the TIMI Study Group using an independent copy of the trial database.</p>
              </sec>
            </sec>
            <sec sec-type="results" id="jah35911-sec-0015">
              <title>Results</title>
              <sec id="jah35911-sec-0016">
                <title>ω3‐PUFA Plasma Content at Baseline</title>
                <p>The long‐chain ω3‐PUFAs (EPA, DHA, DPA) comprised 85.6% of the total ω3‐PUFA content in plasma samples. Among the individual ω3‐PUFAs, the fatty acid that contributed the highest relative proportion to the total ω3 content was DHA (52.5%), followed by EPA (19.6%), ALA (14.4%), and DPA (13.5%) (Figure <xref rid="jah35911-fig-0001" ref-type="fig">1</xref>). A moderate‐to‐strong correlation (<italic>r</italic>=0.46 to 0.67, all <italic>P</italic>&lt;0.001) was seen among the 3 long‐chain ω3‐PUFAs EPA, DPA, and DHA, whereas the correlation was weaker between ALA and the 3 long‐chain ω3‐PUFAs (<italic>r</italic>=−0.14 to 0.26, all <italic>P</italic>&lt;0.001; Table <xref rid="jah35911-sup-0001" ref-type="supplementary-material">S1</xref>).</p>
                <fig fig-type="Figure" xml:lang="en" id="jah35911-fig-0001" orientation="portrait" position="float">
                  <label>Figure 1</label>
                  <caption>
                    <title>Relative proportion of ω3‐polyunsaturated fatty acids subtypes as compared with total ω3‐PUFA content and total fatty acid (FA) content overall.</title>
                    <p>ALA indicates α‐linolenic acid; DHA, docosahexaenoic acid; DPA, docosapentaenoic acid; EPA, eicosapentaenoic acid; and ω3‐PUFA, ω3‐polyunsaturated fatty acids.</p>
                  </caption>
                  <graphic id="jats-graphic-1" xlink:href="JAH3-10-e017401-g001"/>
                </fig>
              </sec>
              <sec id="jah35911-sec-0017">
                <title>Baseline Characteristics</title>
                <p>Overall, the mean age of the study population was 63.9 years; 36.2% were female. Patients with higher long‐chain marine‐based ω3‐PUFA content (ie, the arithmetic sum of EPA, DPA, and DHA fractions) were more likely to be female, older, have lower estimated glomerular filtration rate, a history of hypertension, lower triglycerides and higher high‐density lipoprotein concentrations, and were less likely to be smokers (<xref rid="jah35911-tbl-0001" ref-type="table">Table</xref>). Patients with higher quartiles of ALA were more likely to be male, have a history of diabetes mellitus, lower low‐density lipoprotein cholesterol and high‐density lipoprotein cholesterol levels, and be less likely to have a history of hypertension and heart failure (Table <xref rid="jah35911-sup-0001" ref-type="supplementary-material">S2</xref>).</p>
              </sec>
              <sec id="jah35911-sec-0018">
                <title>ω3‐Polyunsaturated Fatty Acid Plasma Content and Cardiovascular Outcomes</title>
                <p>After multivariable adjustment, patients with higher plasma content of the long‐chain ω3‐PUFAs had 18% lower odds of cardiovascular death (adjusted odds ratio per 1 SD, 0.82; 95% CI, 0.68–0.98; Figure <xref rid="jah35911-fig-0002" ref-type="fig">2A</xref>). Although directional consistency was seen across all individual ω3‐PUFA subtypes, the magnitude of the relationship was not as strong for ALA (adjusted odds ratio per 1 SD, 0.92; 95% CI, 0.74–1.14) when compared with the long chain ω3‐PUFAs. Notably, the observed relationship between the long‐chain ω3‐PUFAs and risk of cardiovascular death was largely driven by a 27% lower odds of sudden cardiac death (adjusted odds ratio per 1 SD, 0.73; 95% CI, 0.55–0.97; Figure <xref rid="jah35911-fig-0002" ref-type="fig">2B</xref>), whereas there was no significant association with cardiovascular death unrelated to sudden cardiac death (Figures <xref rid="jah35911-sup-0001" ref-type="supplementary-material">S1 and S2</xref>).</p>
                <fig fig-type="Figure" xml:lang="en" id="jah35911-fig-0002" orientation="portrait" position="float">
                  <label>Figure 2</label>
                  <caption>
                    <title>Multivariable adjusted odds ratios per 1‐SD increase in ω3‐polyunsaturated fatty acid subtype content for cardiovascular death (<bold>A</bold>) and sudden cardiac death (<bold>B</bold>).</title>
                    <p>The models were adjusted for age, sex, estimated glomerular filtration rate, hypertension, prior myocardial infarction, heart failure, diabetes mellitus, smoking, statin use, high‐density lipoprotein cholesterol, low‐density lipoprotein cholesterol, triglycerides, body mass index, race, region, index diagnosis, and randomized treatment arm. The long chain ω3‐polyunsaturated fatty acids include EPA, DPA, and DHA. Adj. OR indicated adjusted odds ratio; ALA, α‐linolenic acid; CV, cardiovascular; DHA, docosahexaenoic acid; DPA, docosapentaenoic acid; and EPA, eicosapentaenoic acid.</p>
                  </caption>
                  <graphic id="jats-graphic-3" xlink:href="JAH3-10-e017401-g003"/>
                </fig>
                <p>When considered by quartile, a stepwise decrease in the odds of sudden cardiac death was observed with higher long‐chain ω3‐PUFA content (<italic>P</italic> trend=0.025) (Figure <xref rid="jah35911-fig-0003" ref-type="fig">3</xref>). Although underpowered, a qualitatively similar gradient of risk was seen for the individual fatty acids DPA (<italic>P</italic> trend=0.061) and EPA (<italic>P</italic> trend=0.079) (Figure <xref rid="jah35911-fig-0003" ref-type="fig">3</xref>). Adjusted natural cubic regression splines suggest a consistent, nearly linear decrease in the probability of sudden cardiac death for increasing proportions of the long‐chain ω3‐PUFAs (Figure <xref rid="jah35911-fig-0004" ref-type="fig">4</xref>).</p>
                <fig fig-type="Figure" xml:lang="en" id="jah35911-fig-0003" orientation="portrait" position="float">
                  <label>Figure 3</label>
                  <caption>
                    <title>Multivariable adjusted odds ratios for quartiles of ω3‐polyunsaturated fatty acid (ω3‐PUFA) subtypes for sudden cardiac death.</title>
                    <p>The models were adjusted for age, sex, estimated glomerular filtration rate, hypertension, prior myocardial infarction, heart failure, diabetes mellitus, smoking, statin use, high‐density lipoprotein cholesterol, low‐density lipoprotein cholesterol, triglycerides, body mass index, race, region, index diagnosis, and randomized treatment arm. ALA indicates α‐linolenic acid; DHA, docosahexaenoic acid; DPA, docosapentaenoic acid; and EPA, eicosapentaenoic acid.</p>
                  </caption>
                  <graphic id="jats-graphic-5" xlink:href="JAH3-10-e017401-g002"/>
                </fig>
                <fig fig-type="Figure" xml:lang="en" id="jah35911-fig-0004" orientation="portrait" position="float">
                  <label>Figure 4</label>
                  <caption>
                    <title>Multivariable adjusted splines for long‐chain marine‐based ω3‐polyunsaturated fatty acid (ω3‐PUFA) content (EPA, DHA, DPA) and sudden cardiac death.</title>
                    <p>The <italic>x</italic> axis is truncated at the 99.5 percentile of the distribution. Adjusted for age, sex, estimated glomerular filtration rate, hypertension, prior myocardial infarction, heart failure, diabetes mellitus, smoking, statin use, high‐density lipoprotein cholesterol, low‐density lipoprotein cholesterol, triglycerides, body mass index, race, region, index diagnosis, and randomized treatment arm. ALA indicates α‐linolenic acid; DHA, docosahexaenoic acid; DPA, docosapentaenoic acid; and EPA, eicosapentaenoic acid. P‐linearity = 0.87 (indicating that non‐linearity cannot be rejected).</p>
                  </caption>
                  <graphic id="jats-graphic-7" xlink:href="JAH3-10-e017401-g004"/>
                </fig>
                <p>There was a consistent relationship between the long‐chain ω3‐PUFAs and the odds of sudden cardiac death among prespecified subgroups (all <italic>P</italic> values for interaction &gt;0.32), including stratification on the basis of high versus low baseline triglyceride concentration (Figure <xref rid="jah35911-sup-0001" ref-type="supplementary-material">S3</xref>).</p>
                <p>No significant associations were found for any of the ω3 fatty acids, either alone or in combination, with any of the other outcomes of interest, including myocardial infarction, atrial fibrillation, or early post‐ACS ventricular tachycardia, either when tested as a continuous variable (Figure <xref rid="jah35911-sup-0001" ref-type="supplementary-material">S1</xref>) or categorized by quartiles (Figure <xref rid="jah35911-sup-0001" ref-type="supplementary-material">S2</xref>). These relationships were all directionally consistent when the association between total ω3‐PUFA (ie, combining long‐chain ω3‐PUFAs and ALA) and outcomes was examined (Figure <xref rid="jah35911-sup-0001" ref-type="supplementary-material">S4</xref>). Sensitivity analyses using only fasting samples yielded similar results with directionally concordant point estimates (Figures <xref rid="jah35911-sup-0001" ref-type="supplementary-material">S5 through S7</xref>).</p>
              </sec>
            </sec>
            <sec sec-type="discussion" id="jah35911-sec-0019">
              <title>Discussion</title>
              <p>In a large clinical trial population of patients after a non–ST‐segment–elevation ACS, we observed an inverse relationship between plasma long‐chain ω3 fatty acid content and the odds of cardiovascular and sudden cardiac death independent of traditional risk factors. Although directional consistency was seen across the ω3 subtypes, the magnitude of the effect appeared to be greatest for the long‐chain marine‐based ω3‐PUFAs including DHA, DPA, and EPA. Together, these findings lend support to the emerging evidence that suggests that certain types of ω3 supplementation may reduce the risk of adverse cardiovascular outcomes in higher‐risk populations.</p>
              <p>Current guidelines of the American Heart Association suggest ω3‐PUFA supplementation or consumption from seafood may be reasonable to help prevent sudden cardiac death in patients with coronary heart disease.<xref rid="jah35911-bib-0019" ref-type="ref"><sup>19</sup></xref>, <xref rid="jah35911-bib-0020" ref-type="ref"><sup>20</sup></xref> However, despite supportive evidence from observational studies, data from clinical trials remain inconsistent.<xref rid="jah35911-bib-0005" ref-type="ref"><sup>5</sup></xref>, <xref rid="jah35911-bib-0006" ref-type="ref"><sup>6</sup></xref>, <xref rid="jah35911-bib-0007" ref-type="ref"><sup>7</sup></xref>, <xref rid="jah35911-bib-0021" ref-type="ref"><sup>21</sup></xref>, <xref rid="jah35911-bib-0022" ref-type="ref"><sup>22</sup></xref>, <xref rid="jah35911-bib-0023" ref-type="ref"><sup>23</sup></xref> Some of the inconsistency between findings may be explained partly by the patient population studied and differences in the dosing, type, and quality of the ω3‐PUFAs.<xref rid="jah35911-bib-0003" ref-type="ref"><sup>3</sup></xref>, <xref rid="jah35911-bib-0004" ref-type="ref"><sup>4</sup></xref>, <xref rid="jah35911-bib-0005" ref-type="ref"><sup>5</sup></xref>, <xref rid="jah35911-bib-0006" ref-type="ref"><sup>6</sup></xref>, <xref rid="jah35911-bib-0007" ref-type="ref"><sup>7</sup></xref>, <xref rid="jah35911-bib-0008" ref-type="ref"><sup>8</sup></xref>
</p>
              <p>To date, the relationship between circulating ω3‐PUFA content and cardiovascular events in patients after ACS is not well established. Prior observational studies have suggested an association between plasma ω3‐PUFA and lower risk of sudden cardiac death in patients without a history of cardiovascular disease or those with stable atherosclerotic disease.<xref rid="jah35911-bib-0024" ref-type="ref"><sup>24</sup></xref>, <xref rid="jah35911-bib-0025" ref-type="ref"><sup>25</sup></xref> In contrast, in a relatively small investigation among 460 patients after recent ACS, red blood cell ω3‐PUFA content was not significantly associated with cardiac or all‐cause death.<xref rid="jah35911-bib-0026" ref-type="ref"><sup>26</sup></xref>
</p>
              <p>Building on this evidence, earlier trials demonstrated that low‐dose (up to 1 g/d) ω3‐PUFA supplementation may offer protective effects among patients with recent acute myocardial infarction with reduced risk of cardiovascular death and in particular sudden cardiac death.<xref rid="jah35911-bib-0008" ref-type="ref"><sup>8</sup></xref> In contrast, 2 large and well‐conducted randomized controlled trials in primary prevention were unable to demonstrate a significant benefit for low‐dose ω3 supplementation for reducing major adverse cardiovascular events,<xref rid="jah35911-bib-0006" ref-type="ref"><sup>6</sup></xref>, <xref rid="jah35911-bib-0007" ref-type="ref"><sup>7</sup></xref> although a significant reduction in the secondary outcome of coronary heart disease was seen in one of the studies.<xref rid="jah35911-bib-0007" ref-type="ref"><sup>7</sup></xref>
</p>
              <p>At higher doses (4 g/d), the REDUCE‐IT (Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention) trial showed significant reductions in major adverse cardiovascular events including cardiovascular death in patients with hypertriglyceridemia and either known atherosclerotic cardiovascular disease or diabetes mellitus.<xref rid="jah35911-bib-0005" ref-type="ref"><sup>5</sup></xref> Unlike the trials with neutral findings that studied a low‐dose (up to 1 g/d) combination of DHA and EPA, the REDUCE‐IT trial tested a substantially higher dose regimen of icosapent ethyl, a purified EPA ethyl ester. It remains elusive whether the type of the ω3‐PUFA or the higher dose may have contributed to the observed salutary effects, in addition to the potentially harmful use of mineral oil in the control arm.<xref rid="jah35911-bib-0027" ref-type="ref"><sup>27</sup></xref> Although several distinct effects of DHA and EPA have been suggested to be exert cardioprotective mechanisms,<xref rid="jah35911-bib-0028" ref-type="ref"><sup>28</sup></xref> the STRENGTH (A Long‐Term Outcomes Study to Assess Statin Residual Risk Reduction With Epanova in High CV Risk Patients With Hypertriglyceridemia) trial (<ext-link ext-link-type="uri" xlink:href="http://ClinicalTrials.gov">ClinicalTrials.gov</ext-link> Identifier: NCT02104817) studying the combination of higher‐dose DHA and EPA (4 g) was more recently stopped early for futility.<xref rid="jah35911-bib-0029" ref-type="ref"><sup>29</sup></xref>, <xref rid="jah35911-bib-0030" ref-type="ref"><sup>30</sup></xref> It is possible that the specific formulation of icosapent ethyl is responsible for the beneficial treatment effects or that DHA counters the beneficial effects.<xref rid="jah35911-bib-0028" ref-type="ref"><sup>28</sup></xref>
</p>
              <p>In the current study, although the individual subtypes of long‐chain ω3‐PUFAs showed a directionally concordant relationship with sudden cardiac death, the relationship appeared to be more attenuated for ALA. However, the proportion of omega‐3 fatty acids represented by ALA, as with the other subtypes, was relatively small and therefore underpowered. ALA also serves as a biologic precursor to the long chain ω3‐PUFAs; therefore, marine‐sourced intake is not required to increase long‐chain ω3‐PUFA content. However, the conversion efficiency of ALA to DHA or EPA is low. Furthermore, the relationship between ALA and risk of sudden cardiac death appeared stronger when assessed in fasting samples. Nonetheless, evidence on ALA has been more limited, and previous observational studies and clinical trials provide conflicting evidence on its protective effects.<xref rid="jah35911-bib-0023" ref-type="ref"><sup>23</sup></xref>, <xref rid="jah35911-bib-0031" ref-type="ref"><sup>31</sup></xref>, <xref rid="jah35911-bib-0032" ref-type="ref"><sup>32</sup></xref>, <xref rid="jah35911-bib-0033" ref-type="ref"><sup>33</sup></xref>
</p>
              <p>Several pathobiological mechanisms have been suggested to be responsible for the favorable effects of increased ω3‐PUFA intake, although their dose‐response relationship and clinical implications at usual dietary intake remains unclear.<xref rid="jah35911-bib-0002" ref-type="ref"><sup>2</sup></xref> Despite conflicting data,<xref rid="jah35911-bib-0034" ref-type="ref"><sup>34</sup></xref> the antiarrhythmic properties of ω3‐PUFAs have been described as their predominant salutary effect.<xref rid="jah35911-bib-0011" ref-type="ref"><sup>11</sup></xref>, <xref rid="jah35911-bib-0020" ref-type="ref"><sup>20</sup></xref>, <xref rid="jah35911-bib-0035" ref-type="ref"><sup>35</sup></xref>, <xref rid="jah35911-bib-0036" ref-type="ref"><sup>36</sup></xref> Interestingly, we did not observe any association between ω3‐PUFAs and early post‐ACS ventricular tachycardia that may have accounted for the observed decrease in odds of sudden cardiac death. The continuous electrocardiogram monitoring was only recorded for the first 7 days after randomization, and a possible effect could have emerged at a later time point. Similarly, no association between ω3‐PUFAs and risk of atrial fibrillation was found. However, atrial arrhythmias may be more related to atrial structural abnormalities, rather than the change in ischemia‐induced resting membrane depolarization that has been hypothesized to be influenced by ω3‐PUFAs. However, the hypothesis of a membrane‐stabilizing effect through ω3‐PUFAs has been challenged by a few studies that even suggested possible proarrhythmic properties.<xref rid="jah35911-bib-0037" ref-type="ref"><sup>37</sup></xref>, <xref rid="jah35911-bib-0038" ref-type="ref"><sup>38</sup></xref> In the REDUCE‐IT and STRENGTH trials, a surprising increase in risk of atrial fibrillation was reported despite substantial reductions in sudden cardiac death.<xref rid="jah35911-bib-0005" ref-type="ref"><sup>5</sup></xref>, <xref rid="jah35911-bib-0030" ref-type="ref"><sup>30</sup></xref> However, this was a secondary safety end point, and differences in risk of atrial fibrillation have not been reported in prior trials of n‐3 PUFA supplements, whereas observational studies of fish consumption have shown inverse associations with risk of atrial fibrillation.</p>
              <sec id="jah35911-sec-0020">
                <title>Limitations</title>
                <p>Although this study benefited from a large and well‐characterized patient cohort, with cardiovascular events that were adjudicated by an independent and blinded clinical end points committee, there are limitations that should be noted. First, because the study population was hospitalized with an acute ACS, fasting samples were only available in a subset of the total patient cohort; however, sensitivity analyses provided qualitatively similar results. Furthermore, the effects of recent dietary intake on omega 3 fatty acids is not always predictable. In addition, Holter monitoring was performed for a period of 7 days, which allowed systematic capture of only early post‐ACS ventricular tachycardia. Plasma levels of fatty acids may also reflect a shorter term of dietary fat intakes as compared with adipose tissue samples.<xref rid="jah35911-bib-0039" ref-type="ref"><sup>39</sup></xref> Moreover, as most patients in included in this trial were White, these results might not be generalizable to other races. Because this analysis was exploratory in nature, we did not control for multiple testing, and despite adjusting for a large number of clinically relevant variables, potential residual confounding cannot be ruled out.</p>
              </sec>
            </sec>
            <sec sec-type="conclusions" id="jah35911-sec-0021">
              <title>Conclusions</title>
              <p>In patients with a non–ST‐segment–elevation ACS, a higher relative proportion of long‐chain ω3‐PUFA content in plasma is associated with lower odds of sudden cardiac death, independent of traditional risk factors and lipids.</p>
            </sec>
            <sec id="jah35911-sec-0022">
              <title>Sources of Funding</title>
              <p>Research reported in this article was supported by National Institutes of Health National Center for Advancing Translational Sciences under award number NHLBI R01HL098280. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Dr Zelniker is supported by the Deutsche Forschungsgemeinschaft (DFG, ZE 1109/1‐1). The MERLIN‐TIMI 36 trial was funded by CV Therapeutics.</p>
            </sec>
            <sec sec-type="COI-statement" id="jah35911-sec-0023">
              <title>Disclosures</title>
              <p>Dr Zelniker was supported by a research grant of the Deutsche Forschungsgemeinschaft (DFG, ZE 1109/1‐1) and has received consulting fees and honoraria from AstraZeneca and Boehringer Ingelheim. Dr Morrow reports grants from Anthos Therapeutics, Daiichi Sankyo, Eisai, GlaxoSmithKline, Medicines Company, Pfizer, Quark, Regeneron, Siemens, Takeda, and Zora Biosciences; grants and personal fees from AstraZeneca, Merck &amp; Co, Novartis, and Roche Diagnostics; and personal fees from Bayer Pharma, and InCarda, outside the submitted work. Dr Morrow is a member of the TIMI Study Group, which has received institutional research grant support through Brigham and Women's Hospital from Abbott, Amgen, Aralez, AstraZeneca, Bayer HealthCare Pharmaceuticals, Inc., BRAHMS, Daiichi‐Sankyo, Eisai, GlaxoSmithKline, Intarcia, Janssen, MedImmune, Merck, Novartis, Pfizer, Poxel, Quark Pharmaceuticals, Regeneron, Roche, Siemens, Takeda, The Medicines Company, and Zora Biosciences. Dr Scirica reports institutional research grants to Brigham and Women's Hospital from AstraZeneca, Eisai, Merck, Novartis, NovoNordisk, and Pfizer; consulting fees from AbbVie, Allergan, AstraZeneca, Boehringer Ingelheim, Eisai, Elsevier Practice Update Cardiology, Esperion, Hamni, Lexicon, Medtronic, Merck, and NovoNordisk; and equity in HEALTH[at]SCALE. Dr Scirica is a member of the TIMI Study Group, which has received institutional research grant support through Brigham and Women's Hospital from: Abbott, Amgen, Aralez, AstraZeneca, Bayer HealthCare Pharmaceuticals, Inc., BRAHMS, Daiichi‐Sankyo, Eisai, GlaxoSmithKline, Intarcia, Janssen, MedImmune, Merck, Novartis, Pfizer, Poxel, Quark Pharmaceuticals, Roche, Takeda, The Medicines Company, and Zora Biosciences. Dr Furtado reports no conflicts of interest related to this article. J. Guo is a member of the TIMI Study Group, which has received institutional research grant support through Brigham and Women's Hospital from Abbott, Amgen, Aralez, AstraZeneca, Bayer HealthCare Pharmaceuticals, Inc., BRAHMS, Daiichi‐Sankyo, Eisai, GlaxoSmithKline, Intarcia, Janssen, MedImmune, Merck, Novartis, Pfizer, Poxel, Quark Pharmaceuticals, Regeneron, Roche, Siemens, Takeda, The Medicines Company, and Zora Biosciences. Dr Mozaffarian reports research funding from the National Institutes of Health, the Gates Foundation, and the Rockefeller Foundation; personal fees from GOED, Danone, Indigo Agriculture, Motif FoodWorks, Amarin, Acasti Pharma, Cleveland Clinic Foundation, and America's Test Kitchen; has been a member of the scientific advisory boards of Beren Therapeutics, Brightseed, Calibrate, DayTwo, Elysium Health, Filtricine, Foodome, HumanCo, January.ai, and Tiny Organics; and received chapter royalties from UpToDate; all outside the submitted work. Dr Sabatine reports the following conflicts of interest: research grant support through Brigham and Women's Hospital from Amgen, Anthos Therapeutics, AstraZeneca, Bayer, Daiichi‐Sankyo, Eisai, Intarcia, Medicines Company, MedImmune, Merck, Novartis, Pfizer, Quark Pharmaceuticals, Takeda; and has been a consultant for Althera, Amgen, Anthos Therapeutics, AstraZeneca, Bristol‐Myers Squibb, CVS Caremark, DalCor, Dr Reddy's Laboratories, Dyrnamix, Esperion, IFM Therapeutics, Intarcia, Janssen Research and Development, Medicines Company, MedImmune, Merck, and Novartis. Dr O'Donoghue has received grant funding via Brigham and Women's Hospital from Amgen, Medicines Company, Novartis, Merck, Eisai, AstraZeneca and Medimmune, as well as consulting fees from Amgen, AstraZeneca, Novartis, and Janssen.</p>
            </sec>
            <sec id="jah35911-sec-0024">
              <table-wrap id="jah35911-tbl-0001" xml:lang="en" content-type="Table" orientation="portrait" position="float">
                <label>Table 1</label>
                <caption>
                  <p>Baseline Characteristics by Quartiles of Long‐Chain ω3‐Polyunsaturated Fatty Acids (EPA, DPA, DHA)</p>
                </caption>
                <table frame="hsides" rules="groups">
                  <col style="border-right:solid 1px #000000" span="1"/>
                  <col style="border-right:solid 1px #000000" span="1"/>
                  <col style="border-right:solid 1px #000000" span="1"/>
                  <col style="border-right:solid 1px #000000" span="1"/>
                  <col style="border-right:solid 1px #000000" span="1"/>
                  <col style="border-right:solid 1px #000000" span="1"/>
                  <col style="border-right:solid 1px #000000" span="1"/>
                  <thead valign="top">
                    <tr style="border-bottom:solid 1px #000000">
                      <th align="left" valign="top" rowspan="1" colspan="1">Characteristic</th>
                      <th align="center" valign="top" rowspan="1" colspan="1">Total, N=2407</th>
                      <th align="center" valign="top" rowspan="1" colspan="1">Q1, n=602</th>
                      <th align="center" valign="top" rowspan="1" colspan="1">Q2, n=602</th>
                      <th align="center" valign="top" rowspan="1" colspan="1">Q3, n=602</th>
                      <th align="center" valign="top" rowspan="1" colspan="1">Q4, n=601</th>
                      <th align="center" valign="top" rowspan="1" colspan="1"><italic>P</italic> Value for Trend</th>
                    </tr>
                  </thead>
                  <tbody>
                    <tr>
                      <td align="left" rowspan="1" colspan="1">Age, y</td>
                      <td align="left" rowspan="1" colspan="1">63.9±10.8</td>
                      <td align="left" rowspan="1" colspan="1">61.5±11.1</td>
                      <td align="left" rowspan="1" colspan="1">63.6±11.1</td>
                      <td align="left" rowspan="1" colspan="1">65.0±10.3</td>
                      <td align="left" rowspan="1" colspan="1">65.4±10.2</td>
                      <td align="char" char="." rowspan="1" colspan="1">&lt;0.0001</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1">Female sex</td>
                      <td align="left" rowspan="1" colspan="1">871 (36.2%)</td>
                      <td align="left" rowspan="1" colspan="1">207 (34.4%)</td>
                      <td align="left" rowspan="1" colspan="1">208 (35.0%)</td>
                      <td align="left" rowspan="1" colspan="1">215 (35.7%)</td>
                      <td align="left" rowspan="1" colspan="1">241 (40.1%)</td>
                      <td align="char" char="." rowspan="1" colspan="1">0.037</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1">White</td>
                      <td align="left" rowspan="1" colspan="1">2347 (97.5%)</td>
                      <td align="left" rowspan="1" colspan="1">581 (96.5%)</td>
                      <td align="left" rowspan="1" colspan="1">583 (96.8%)</td>
                      <td align="left" rowspan="1" colspan="1">592 (98.3%)</td>
                      <td align="left" rowspan="1" colspan="1">591 (98.3%)</td>
                      <td align="char" char="." rowspan="1" colspan="1">0.014</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1">Current smoker</td>
                      <td align="left" rowspan="1" colspan="1">578 (24.0%)</td>
                      <td align="left" rowspan="1" colspan="1">189 (31.4%)</td>
                      <td align="left" rowspan="1" colspan="1">154 (25.6%)</td>
                      <td align="left" rowspan="1" colspan="1">137 (22.7%)</td>
                      <td align="left" rowspan="1" colspan="1">98 (16.3%)</td>
                      <td align="char" char="." rowspan="1" colspan="1">&lt;0.0001</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1">Diabetes mellitus</td>
                      <td align="left" rowspan="1" colspan="1">800 (33.2%)</td>
                      <td align="left" rowspan="1" colspan="1">228 (37.9%)</td>
                      <td align="left" rowspan="1" colspan="1">196 (32.6%)</td>
                      <td align="left" rowspan="1" colspan="1">188 (31.2%)</td>
                      <td align="left" rowspan="1" colspan="1">188 (31.3%)</td>
                      <td align="char" char="." rowspan="1" colspan="1">0.014</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1">Prior HF</td>
                      <td align="left" rowspan="1" colspan="1">573 (23.8%)</td>
                      <td align="left" rowspan="1" colspan="1">140 (23.3%)</td>
                      <td align="left" rowspan="1" colspan="1">137 (22.8%)</td>
                      <td align="left" rowspan="1" colspan="1">133 (22.1%)</td>
                      <td align="left" rowspan="1" colspan="1">163 (27.1%)</td>
                      <td align="char" char="." rowspan="1" colspan="1">0.16</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1">Index event NSTEMI</td>
                      <td align="left" rowspan="1" colspan="1">1169 (49.7%)</td>
                      <td align="left" rowspan="1" colspan="1">282 (47.8%)</td>
                      <td align="left" rowspan="1" colspan="1">302 (51.6%)</td>
                      <td align="left" rowspan="1" colspan="1">304 (51.5%)</td>
                      <td align="left" rowspan="1" colspan="1">281 (48.0%)</td>
                      <td align="char" char="." rowspan="1" colspan="1">0.96</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1">Prior MI</td>
                      <td align="left" rowspan="1" colspan="1">886 (37.2%)</td>
                      <td align="left" rowspan="1" colspan="1">202 (33.8%)</td>
                      <td align="left" rowspan="1" colspan="1">214 (35.9%)</td>
                      <td align="left" rowspan="1" colspan="1">225 (37.9 %)</td>
                      <td align="left" rowspan="1" colspan="1">245 (41.2%)</td>
                      <td align="char" char="." rowspan="1" colspan="1">0.007</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1">Prior coronary revascularization</td>
                      <td align="left" rowspan="1" colspan="1">620 (25.8%)</td>
                      <td align="left" rowspan="1" colspan="1">170 (28.3%)</td>
                      <td align="left" rowspan="1" colspan="1">167 (27.8%)</td>
                      <td align="left" rowspan="1" colspan="1">132 (21.9%)</td>
                      <td align="left" rowspan="1" colspan="1">151 (25.1%)</td>
                      <td align="char" char="." rowspan="1" colspan="1">0.054</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1">Hypertension</td>
                      <td align="left" rowspan="1" colspan="1">1826 (76.3%)</td>
                      <td align="left" rowspan="1" colspan="1">433 (72.2%)</td>
                      <td align="left" rowspan="1" colspan="1">458 (76.6%)</td>
                      <td align="left" rowspan="1" colspan="1">461 (77.1%)</td>
                      <td align="left" rowspan="1" colspan="1">474 (79.4%)</td>
                      <td align="char" char="." rowspan="1" colspan="1">0.004</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1">Hyperlipidemia</td>
                      <td align="left" rowspan="1" colspan="1">1441 (66.4%)</td>
                      <td align="left" rowspan="1" colspan="1">388 (69.9%)</td>
                      <td align="left" rowspan="1" colspan="1">357 (66.7%)</td>
                      <td align="left" rowspan="1" colspan="1">342 (63.2%)</td>
                      <td align="left" rowspan="1" colspan="1">354 (65.7%)</td>
                      <td align="char" char="." rowspan="1" colspan="1">0.071</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1">BMI, kg/m<sup>2</sup>
</td>
                      <td align="left" rowspan="1" colspan="1">29.0±5.5</td>
                      <td align="left" rowspan="1" colspan="1">29.5±5.5</td>
                      <td align="left" rowspan="1" colspan="1">29.0±5.1</td>
                      <td align="left" rowspan="1" colspan="1">28.9±6.8</td>
                      <td align="left" rowspan="1" colspan="1">28.5±4.5</td>
                      <td align="char" char="." rowspan="1" colspan="1">0.002</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1">eGFR, mL/min per 1.73 m<sup>2</sup>
</td>
                      <td align="left" rowspan="1" colspan="1">75.5±23.6</td>
                      <td align="left" rowspan="1" colspan="1">77.1±25.1</td>
                      <td align="left" rowspan="1" colspan="1">75.9±23.2</td>
                      <td align="left" rowspan="1" colspan="1">75.4±23.2</td>
                      <td align="left" rowspan="1" colspan="1">73.6±22.6</td>
                      <td align="char" char="." rowspan="1" colspan="1">0.011</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1">Total cholesterol, mg/dL</td>
                      <td align="left" rowspan="1" colspan="1">198.1±54.9</td>
                      <td align="left" rowspan="1" colspan="1">198.8±55.8</td>
                      <td align="left" rowspan="1" colspan="1">198.7±57.5</td>
                      <td align="left" rowspan="1" colspan="1">195.6±53.0</td>
                      <td align="left" rowspan="1" colspan="1">199.5±53.3</td>
                      <td align="char" char="." rowspan="1" colspan="1">0.92</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1">LDL‐C, mg/dL</td>
                      <td align="left" rowspan="1" colspan="1">119.9±48.3</td>
                      <td align="left" rowspan="1" colspan="1">116.9±46.5</td>
                      <td align="left" rowspan="1" colspan="1">120.5±52.5</td>
                      <td align="left" rowspan="1" colspan="1">119.4±45.9</td>
                      <td align="left" rowspan="1" colspan="1">122.7±48.2</td>
                      <td align="char" char="." rowspan="1" colspan="1">0.080</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1">HDL‐C, mg/dL</td>
                      <td align="left" rowspan="1" colspan="1">45.1±15.3</td>
                      <td align="left" rowspan="1" colspan="1">41.3±15.4</td>
                      <td align="left" rowspan="1" colspan="1">44.1±13.7</td>
                      <td align="left" rowspan="1" colspan="1">46.2±15.6</td>
                      <td align="left" rowspan="1" colspan="1">49.0±15.5</td>
                      <td align="char" char="." rowspan="1" colspan="1">&lt;0.0001</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1">Triglycerides, mg/dL</td>
                      <td align="left" rowspan="1" colspan="1">176.0±141.9</td>
                      <td align="left" rowspan="1" colspan="1">223.5±218.0</td>
                      <td align="left" rowspan="1" colspan="1">181.7±122.5</td>
                      <td align="left" rowspan="1" colspan="1">155.3±86.3</td>
                      <td align="left" rowspan="1" colspan="1">143.0±81.2</td>
                      <td align="char" char="." rowspan="1" colspan="1">&lt;0.0001</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1">hs‐CRP, mg/dL</td>
                      <td align="left" rowspan="1" colspan="1">13.8±20.8</td>
                      <td align="left" rowspan="1" colspan="1">13.6±19.7</td>
                      <td align="left" rowspan="1" colspan="1">14.9±21.8</td>
                      <td align="left" rowspan="1" colspan="1">14.0±21.1</td>
                      <td align="left" rowspan="1" colspan="1">12.7±20.5</td>
                      <td align="char" char="." rowspan="1" colspan="1">0.37</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1">Aspirin</td>
                      <td align="left" rowspan="1" colspan="1">2316 (96.2%)</td>
                      <td align="left" rowspan="1" colspan="1">575 (95.5%)</td>
                      <td align="left" rowspan="1" colspan="1">577 (95.9%)</td>
                      <td align="left" rowspan="1" colspan="1">584 (97.0%)</td>
                      <td align="left" rowspan="1" colspan="1">580 (96.5%)</td>
                      <td align="char" char="." rowspan="1" colspan="1">0.23</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1">β‐blocker</td>
                      <td align="left" rowspan="1" colspan="1">2179 (90.5%)</td>
                      <td align="left" rowspan="1" colspan="1">552 (91.7%)</td>
                      <td align="left" rowspan="1" colspan="1">534 (88.7%)</td>
                      <td align="left" rowspan="1" colspan="1">548 (91.0%)</td>
                      <td align="left" rowspan="1" colspan="1">545 (90.7%)</td>
                      <td align="char" char="." rowspan="1" colspan="1">0.89</td>
                    </tr>
                    <tr>
                      <td align="left" rowspan="1" colspan="1">Statin</td>
                      <td align="left" rowspan="1" colspan="1">1843 (76.6%)</td>
                      <td align="left" rowspan="1" colspan="1">457 (75.9%)</td>
                      <td align="left" rowspan="1" colspan="1">470 (78.1%)</td>
                      <td align="left" rowspan="1" colspan="1">461 (76.6%)</td>
                      <td align="left" rowspan="1" colspan="1">455 (75.7%)</td>
                      <td align="char" char="." rowspan="1" colspan="1">0.78</td>
                    </tr>
                  </tbody>
                </table>
                <table-wrap-foot id="jah35911-ntgp-0002">
                  <fn id="jah35911-note-0003">
                    <p>Continuous variables reported as mean (SD). BMI indicates body mass index; DHA, docosahexaenoic acid; DPA, docosapentaenoic acid; eGFR, estimated glomerular filtration rate; EPA, eicosapentaenoic acid; HDL‐C, high‐density lipoprotein cholesterol; HF, heart failure; hs‐CRP, high‐sensitivity C‐reactive protein; LDL‐C, low‐density lipoprotein cholesterol; MI, myocardial infarction; and NSTEMI, non–ST‐segment–elevation myocardial infarction.</p>
                  </fn>
                </table-wrap-foot>
                <permissions>
                  <copyright-holder>John Wiley &amp; Sons, Ltd</copyright-holder>
                </permissions>
              </table-wrap>
            </sec>
            <sec sec-type="supplementary-material">
              <title>Supporting information</title>
              <supplementary-material content-type="local-data" id="jah35911-sup-0001">
                <caption>
                  <p>
Tables S1–S2
</p>
                  <p>
Figures S1–S7
</p>
                </caption>
                <media xlink:href="JAH3-10-e017401-s001.pdf">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
            </sec>
          </body>
          <back>
            <ref-list content-type="cited-references" id="jah35911-bibl-0001">
              <title>References</title>
              <ref id="jah35911-bib-0001">
                <label>1</label>
                <mixed-citation publication-type="journal" id="jah35911-cit-0001"><string-name><surname>Lavie</surname><given-names>CJ</given-names></string-name>, <string-name><surname>Milani</surname><given-names>RV</given-names></string-name>, <string-name><surname>Mehra</surname><given-names>MR</given-names></string-name>, <string-name><surname>Ventura</surname><given-names>HO</given-names></string-name>. <article-title>Omega‐3 polyunsaturated fatty acids and cardiovascular diseases</article-title>. <source xml:lang="en">J Am Coll Cardiol</source>. <year>2009</year>;<volume>54</volume>:<fpage>585</fpage>–<lpage>594</lpage>. DOI: <pub-id pub-id-type="doi">10.1016/j.jacc.2009.02.084</pub-id>
.<pub-id pub-id-type="pmid">19660687</pub-id></mixed-citation>
              </ref>
              <ref id="jah35911-bib-0002">
                <label>2</label>
                <mixed-citation publication-type="journal" id="jah35911-cit-0002"><string-name><surname>Mozaffarian</surname><given-names>D</given-names></string-name>, <string-name><surname>Wu</surname><given-names>JH</given-names></string-name>. <article-title>Omega‐3 fatty acids and cardiovascular disease: Effects on risk factors, molecular pathways, and clinical events</article-title>. <source xml:lang="en">J Am Coll Cardiol</source>. <year>2011</year>;<volume>58</volume>:<fpage>2047</fpage>–<lpage>2067</lpage>. DOI: <pub-id pub-id-type="doi">10.1016/j.jacc.2011.06.063</pub-id>
.<pub-id pub-id-type="pmid">22051327</pub-id></mixed-citation>
              </ref>
              <ref id="jah35911-bib-0003">
                <label>3</label>
                <mixed-citation publication-type="journal" id="jah35911-cit-0003"><string-name><surname>Alexander</surname><given-names>DD</given-names></string-name>, <string-name><surname>Miller</surname><given-names>PE</given-names></string-name>, <string-name><surname>Van Elswyk</surname><given-names>ME</given-names></string-name>, <string-name><surname>Kuratko</surname><given-names>CN</given-names></string-name>, <string-name><surname>Bylsma</surname><given-names>LC</given-names></string-name>. <article-title>A meta‐analysis of randomized controlled trials and prospective cohort studies of eicosapentaenoic and docosahexaenoic long‐chain omega‐3 fatty acids and coronary heart disease risk</article-title>. <source xml:lang="en">Mayo Clin Proc</source>. <year>2017</year>;<volume>92</volume>:<fpage>15</fpage>–<lpage>29</lpage>. DOI: <pub-id pub-id-type="doi">10.1016/j.mayocp.2016.10.018</pub-id>
.<pub-id pub-id-type="pmid">28062061</pub-id></mixed-citation>
              </ref>
              <ref id="jah35911-bib-0004">
                <label>4</label>
                <mixed-citation publication-type="journal" id="jah35911-cit-0004"><string-name><surname>Aung</surname><given-names>T</given-names></string-name>, <string-name><surname>Halsey</surname><given-names>J</given-names></string-name>, <string-name><surname>Kromhout</surname><given-names>D</given-names></string-name>, <string-name><surname>Gerstein</surname><given-names>HC</given-names></string-name>, <string-name><surname>Marchioli</surname><given-names>R</given-names></string-name>, <string-name><surname>Tavazzi</surname><given-names>L</given-names></string-name>, <string-name><surname>Geleijnse</surname><given-names>JM</given-names></string-name>, <string-name><surname>Rauch</surname><given-names>B</given-names></string-name>, <string-name><surname>Ness</surname><given-names>A</given-names></string-name>, <string-name><surname>Galan</surname><given-names>P</given-names></string-name>, et al. <article-title>Associations of omega‐3 fatty acid supplement use with cardiovascular disease risks: meta‐analysis of 10 trials involving 77917 individuals</article-title>. <source xml:lang="en">JAMA Cardiol</source>. <year>2018</year>;<volume>3</volume>:<fpage>225</fpage>–<lpage>234</lpage>. DOI: <pub-id pub-id-type="doi">10.1001/jamacardio.2017.5205</pub-id>
.<pub-id pub-id-type="pmid">29387889</pub-id></mixed-citation>
              </ref>
              <ref id="jah35911-bib-0005">
                <label>5</label>
                <mixed-citation publication-type="journal" id="jah35911-cit-0005"><string-name><surname>Bhatt</surname><given-names>DL</given-names></string-name>, <string-name><surname>Steg</surname><given-names>PG</given-names></string-name>, <string-name><surname>Miller</surname><given-names>M</given-names></string-name>, <string-name><surname>Brinton</surname><given-names>EA</given-names></string-name>, <string-name><surname>Jacobson</surname><given-names>TA</given-names></string-name>, <string-name><surname>Ketchum</surname><given-names>SB</given-names></string-name>, <string-name><surname>Doyle</surname><given-names>RT</given-names><suffix>Jr</suffix></string-name>, <string-name><surname>Juliano</surname><given-names>RA</given-names></string-name>, <string-name><surname>Jiao</surname><given-names>L</given-names></string-name>, <string-name><surname>Granowitz</surname><given-names>C</given-names></string-name>, et al. <article-title>Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia</article-title>. <source xml:lang="en">N Engl J Med</source>. <year>2019</year>;<volume>380</volume>:<fpage>11</fpage>–<lpage>22</lpage>. DOI: <pub-id pub-id-type="doi">10.1056/NEJMoa1812792</pub-id>
.<pub-id pub-id-type="pmid">30415628</pub-id></mixed-citation>
              </ref>
              <ref id="jah35911-bib-0006">
                <label>6</label>
                <mixed-citation publication-type="journal" id="jah35911-cit-0006"><collab collab-type="authors">Group ASC</collab>
, <string-name><surname>Bowman</surname><given-names>L</given-names></string-name>, <string-name><surname>Mafham</surname><given-names>M</given-names></string-name>, <string-name><surname>Wallendszus</surname><given-names>K</given-names></string-name>, <string-name><surname>Stevens</surname><given-names>W</given-names></string-name>, <string-name><surname>Buck</surname><given-names>G</given-names></string-name>, <string-name><surname>Barton</surname><given-names>J</given-names></string-name>, <string-name><surname>Murphy</surname><given-names>K</given-names></string-name>, <string-name><surname>Aung</surname><given-names>T</given-names></string-name>, <string-name><surname>Haynes</surname><given-names>R</given-names></string-name>, et al. <article-title>Effects of n‐3 fatty acid supplements in diabetes mellitus</article-title>. <source xml:lang="en">N Engl J Med</source>. <year>2018</year>;<volume>379</volume>:<fpage>1540</fpage>–<lpage>1550</lpage>.<pub-id pub-id-type="pmid">30146932</pub-id></mixed-citation>
              </ref>
              <ref id="jah35911-bib-0007">
                <label>7</label>
                <mixed-citation publication-type="journal" id="jah35911-cit-0007"><string-name><surname>Manson</surname><given-names>JE</given-names></string-name>, <string-name><surname>Cook</surname><given-names>NR</given-names></string-name>, <string-name><surname>Lee</surname><given-names>I‐M</given-names></string-name>, <string-name><surname>Christen</surname><given-names>W</given-names></string-name>, <string-name><surname>Bassuk</surname><given-names>SS</given-names></string-name>, <string-name><surname>Mora</surname><given-names>S</given-names></string-name>, <string-name><surname>Gibson</surname><given-names>H</given-names></string-name>, <string-name><surname>Albert</surname><given-names>CM</given-names></string-name>, <string-name><surname>Gordon</surname><given-names>D</given-names></string-name>, <string-name><surname>Copeland</surname><given-names>T</given-names></string-name>, et al. <article-title>Marine n‐3 fatty acids and prevention of cardiovascular disease and cancer</article-title>. <source xml:lang="en">N Engl J Med</source>. <year>2019</year>;<volume>380</volume>:<fpage>23</fpage>–<lpage>32</lpage>. DOI: <pub-id pub-id-type="doi">10.1056/NEJMoa1811403</pub-id>
.<pub-id pub-id-type="pmid">30415637</pub-id></mixed-citation>
              </ref>
              <ref id="jah35911-bib-0008">
                <label>8</label>
                <mixed-citation publication-type="journal" id="jah35911-cit-0008"><article-title>GISSI‐Prevenzione Investigators Dietary supplementation with n‐3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI‐Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'infarto miocardico</article-title>. <source xml:lang="en">Lancet</source>. <year>1999</year>;<volume>354</volume>:<fpage>447</fpage>–<lpage>455</lpage>.<pub-id pub-id-type="pmid">10465168</pub-id></mixed-citation>
              </ref>
              <ref id="jah35911-bib-0009">
                <label>9</label>
                <mixed-citation publication-type="journal" id="jah35911-cit-0009"><string-name><surname>Siscovick</surname><given-names>DS</given-names></string-name>, <string-name><surname>Lemaitre</surname><given-names>RN</given-names></string-name>, <string-name><surname>Mozaffarian</surname><given-names>D</given-names></string-name>. <article-title>The fish story: a diet‐heart hypothesis with clinical implications: N‐3 polyunsaturated fatty acids, myocardial vulnerability, and sudden death</article-title>. <source xml:lang="en">Circulation</source>. <year>2003</year>;<volume>107</volume>:<fpage>2632</fpage>–<lpage>2634</lpage>. DOI: <pub-id pub-id-type="doi">10.1161/01.CIR.0000074779.11379.62</pub-id>
.<pub-id pub-id-type="pmid">12782612</pub-id></mixed-citation>
              </ref>
              <ref id="jah35911-bib-0010">
                <label>10</label>
                <mixed-citation publication-type="journal" id="jah35911-cit-0010"><string-name><surname>Mozaffarian</surname><given-names>D</given-names></string-name>, <string-name><surname>Rimm</surname><given-names>EB</given-names></string-name>. <article-title>Fish intake, contaminants, and human health: evaluating the risks and the benefits</article-title>. <source xml:lang="en">JAMA</source>. <year>2006</year>;<volume>296</volume>:<fpage>1885</fpage>–<lpage>1899</lpage>. DOI: <pub-id pub-id-type="doi">10.1001/jama.296.15.1885</pub-id>
<pub-id pub-id-type="pmid">17047219</pub-id></mixed-citation>
              </ref>
              <ref id="jah35911-bib-0011">
                <label>11</label>
                <mixed-citation publication-type="journal" id="jah35911-cit-0011"><string-name><surname>Leaf</surname><given-names>A</given-names></string-name>, <string-name><surname>Kang</surname><given-names>JX</given-names></string-name>, <string-name><surname>Xiao</surname><given-names>YF</given-names></string-name>, <string-name><surname>Billman</surname><given-names>GE</given-names></string-name>. <article-title>Clinical prevention of sudden cardiac death by n‐3 polyunsaturated fatty acids and mechanism of prevention of arrhythmias by n‐3 fish oils</article-title>. <source xml:lang="en">Circulation</source>. <year>2003</year>;<volume>107</volume>:<fpage>2646</fpage>–<lpage>2652</lpage>. DOI: <pub-id pub-id-type="doi">10.1161/01.CIR.0000069566.78305.33</pub-id>
.<pub-id pub-id-type="pmid">12782616</pub-id></mixed-citation>
              </ref>
              <ref id="jah35911-bib-0012">
                <label>12</label>
                <mixed-citation publication-type="journal" id="jah35911-cit-0012"><string-name><surname>Morrow</surname><given-names>DA</given-names></string-name>, <string-name><surname>Scirica</surname><given-names>BM</given-names></string-name>, <string-name><surname>Karwatowska‐Prokopczuk</surname><given-names>E</given-names></string-name>, <string-name><surname>Skene</surname><given-names>A</given-names></string-name>, <string-name><surname>McCabe</surname><given-names>CH</given-names></string-name>, <string-name><surname>Braunwald</surname><given-names>E</given-names></string-name>; <collab collab-type="authors">Investigators M‐T</collab>
. <article-title>Evaluation of a novel anti‐ischemic agent in acute coronary syndromes: design and rationale for the metabolic efficiency with ranolazine for less ischemia in non‐ST‐elevation acute coronary syndromes (MERLIN)‐TIMI 36 trial</article-title>. <source xml:lang="en">Am Heart J</source>. <year>2006</year>;<volume>151</volume>:<fpage>1186</fpage>.e1181–1189. DOI: <pub-id pub-id-type="doi">10.1016/j.ahj.2006.01.004</pub-id>
.</mixed-citation>
              </ref>
              <ref id="jah35911-bib-0013">
                <label>13</label>
                <mixed-citation publication-type="journal" id="jah35911-cit-0013"><string-name><surname>Morrow</surname><given-names>DA</given-names></string-name>, <string-name><surname>Scirica</surname><given-names>BM</given-names></string-name>, <string-name><surname>Karwatowska‐Prokopczuk</surname><given-names>E</given-names></string-name>, <string-name><surname>Murphy</surname><given-names>SA</given-names></string-name>, <string-name><surname>Budaj</surname><given-names>A</given-names></string-name>, <string-name><surname>Varshavsky</surname><given-names>S</given-names></string-name>, <string-name><surname>Wolff</surname><given-names>AA</given-names></string-name>, <string-name><surname>Skene</surname><given-names>A</given-names></string-name>, <string-name><surname>McCabe</surname><given-names>CH</given-names></string-name>, <string-name><surname>Braunwald</surname><given-names>E</given-names></string-name>, et al. <article-title>Effects of ranolazine on recurrent cardiovascular events in patients with non‐ST‐elevation acute coronary syndromes: the MERLIN‐TIMI 36 randomized trial</article-title>. <source xml:lang="en">JAMA</source>. <year>2007</year>;<volume>297</volume>:<fpage>1775</fpage>–<lpage>1783</lpage>.<pub-id pub-id-type="pmid">17456819</pub-id></mixed-citation>
              </ref>
              <ref id="jah35911-bib-0014">
                <label>14</label>
                <mixed-citation publication-type="book" id="jah35911-cit-0014"><string-name><surname>Epidemiology</surname><given-names>GL</given-names></string-name>. <source xml:lang="en">Chapter 10: Case‐Control and Other Study Designs</source>. <publisher-loc>Philadelphia, USA</publisher-loc>:<publisher-name>Elsevier</publisher-name>; <year>2014</year>.</mixed-citation>
              </ref>
              <ref id="jah35911-bib-0015">
                <label>15</label>
                <mixed-citation publication-type="journal" id="jah35911-cit-0015"><string-name><surname>Baylin</surname><given-names>A</given-names></string-name>, <string-name><surname>Kim</surname><given-names>MK</given-names></string-name>, <string-name><surname>Donovan‐Palmer</surname><given-names>A</given-names></string-name>, <string-name><surname>Siles</surname><given-names>X</given-names></string-name>, <string-name><surname>Dougherty</surname><given-names>L</given-names></string-name>, <string-name><surname>Tocco</surname><given-names>P</given-names></string-name>, <string-name><surname>Campos</surname><given-names>H</given-names></string-name>. <article-title>Fasting whole blood as a biomarker of essential fatty acid intake in epidemiologic studies: comparison with adipose tissue and plasma</article-title>. <source xml:lang="en">Am J Epidemiol</source>. <year>2005</year>;<volume>162</volume>:<fpage>373</fpage>–<lpage>381</lpage>. DOI: <pub-id pub-id-type="doi">10.1093/aje/kwi213</pub-id>
.<pub-id pub-id-type="pmid">16014782</pub-id></mixed-citation>
              </ref>
              <ref id="jah35911-bib-0016">
                <label>16</label>
                <mixed-citation publication-type="journal" id="jah35911-cit-0016"><string-name><surname>Patel</surname><given-names>RB</given-names></string-name>, <string-name><surname>Tannenbaum</surname><given-names>S</given-names></string-name>, <string-name><surname>Viana‐Tejedor</surname><given-names>A</given-names></string-name>, <string-name><surname>Guo</surname><given-names>J</given-names></string-name>, <string-name><surname>Im</surname><given-names>K</given-names></string-name>, <string-name><surname>Morrow</surname><given-names>DA</given-names></string-name>, <string-name><surname>Scirica</surname><given-names>BM</given-names></string-name>. <article-title>Serum potassium levels, cardiac arrhythmias, and mortality following non‐ST‐elevation myocardial infarction or unstable angina: insights from MERLIN‐TIMI 36</article-title>. <source xml:lang="en">Eur Heart J Acute Cardiovasc Care</source>. <year>2017</year>;<volume>6</volume>:<fpage>18</fpage>–<lpage>25</lpage>. DOI: <pub-id pub-id-type="doi">10.1177/2048872615624241</pub-id>
.<pub-id pub-id-type="pmid">26714972</pub-id></mixed-citation>
              </ref>
              <ref id="jah35911-bib-0017">
                <label>17</label>
                <mixed-citation publication-type="journal" id="jah35911-cit-0017"><string-name><surname>Scirica</surname><given-names>BM</given-names></string-name>, <string-name><surname>Belardinelli</surname><given-names>L</given-names></string-name>, <string-name><surname>Chaitman</surname><given-names>BR</given-names></string-name>, <string-name><surname>Waks</surname><given-names>JW</given-names></string-name>, <string-name><surname>Volo</surname><given-names>S</given-names></string-name>, <string-name><surname>Karwatowska‐Prokopczuk</surname><given-names>E</given-names></string-name>, <string-name><surname>Murphy</surname><given-names>SA</given-names></string-name>, <string-name><surname>Cheng</surname><given-names>ML</given-names></string-name>, <string-name><surname>Braunwald</surname><given-names>E</given-names></string-name>, <string-name><surname>Morrow</surname><given-names>DA</given-names></string-name>. <article-title>Effect of ranolazine on atrial fibrillation in patients with non‐ST elevation acute coronary syndromes: observations from the MERLIN‐TIMI 36 trial</article-title>. <source xml:lang="en">Europace</source>. <year>2015</year>;<volume>17</volume>:<fpage>32</fpage>–<lpage>37</lpage>. DOI: <pub-id pub-id-type="doi">10.1093/europace/euu217</pub-id>
.<pub-id pub-id-type="pmid">25210025</pub-id></mixed-citation>
              </ref>
              <ref id="jah35911-bib-0018">
                <label>18</label>
                <mixed-citation publication-type="journal" id="jah35911-cit-0018"><string-name><surname>Noma</surname><given-names>H</given-names></string-name>, <string-name><surname>Tanaka</surname><given-names>S</given-names></string-name>. <article-title>Analysis of case‐cohort designs with binary outcomes: improving efficiency using whole‐cohort auxiliary information</article-title>. <source xml:lang="en">Stat Methods Med Res</source>. <year>2017</year>;<volume>26</volume>:<fpage>691</fpage>–<lpage>706</lpage>. DOI: <pub-id pub-id-type="doi">10.1177/0962280214556175</pub-id>
.<pub-id pub-id-type="pmid">25348675</pub-id></mixed-citation>
              </ref>
              <ref id="jah35911-bib-0019">
                <label>19</label>
                <mixed-citation publication-type="journal" id="jah35911-cit-0019"><string-name><surname>Sacks</surname><given-names>FM</given-names></string-name>, <string-name><surname>Lichtenstein</surname><given-names>AH</given-names></string-name>, <string-name><surname>Wu</surname><given-names>JHY</given-names></string-name>, <string-name><surname>Appel</surname><given-names>LJ</given-names></string-name>, <string-name><surname>Creager</surname><given-names>MA</given-names></string-name>, <string-name><surname>Kris‐Etherton</surname><given-names>PM</given-names></string-name>, <string-name><surname>Miller</surname><given-names>M</given-names></string-name>, <string-name><surname>Rimm</surname><given-names>EB</given-names></string-name>, <string-name><surname>Rudel</surname><given-names>LL</given-names></string-name>, <string-name><surname>Robinson</surname><given-names>JG</given-names></string-name>, et al. <article-title>Dietary fats and cardiovascular disease: a presidential advisory from the American Heart Association</article-title>. <source xml:lang="en">Circulation</source>. <year>2017</year>;<volume>136</volume>:<fpage>e1</fpage>–<lpage>e23</lpage>. DOI: <pub-id pub-id-type="doi">10.1161/CIR.0000000000000510</pub-id>
.<pub-id pub-id-type="pmid">28620111</pub-id></mixed-citation>
              </ref>
              <ref id="jah35911-bib-0020">
                <label>20</label>
                <mixed-citation publication-type="journal" id="jah35911-cit-0020"><string-name><surname>Siscovick</surname><given-names>DS</given-names></string-name>, <string-name><surname>Barringer</surname><given-names>TA</given-names></string-name>, <string-name><surname>Fretts</surname><given-names>AM</given-names></string-name>, <string-name><surname>Wu</surname><given-names>JHY</given-names></string-name>, <string-name><surname>Lichtenstein</surname><given-names>AH</given-names></string-name>, <string-name><surname>Costello</surname><given-names>RB</given-names></string-name>, <string-name><surname>Kris‐Etherton</surname><given-names>PM</given-names></string-name>, <string-name><surname>Jacobson</surname><given-names>TA</given-names></string-name>, <string-name><surname>Engler</surname><given-names>MB</given-names></string-name>, <string-name><surname>Alger</surname><given-names>HM</given-names></string-name>, et al. <article-title>Omega‐3 polyunsaturated fatty acid (fish oil) supplementation and the prevention of clinical cardiovascular disease: a science advisory from the American Heart Association</article-title>. <source xml:lang="en">Circulation</source>. <year>2017</year>;<volume>135</volume>:<fpage>e867</fpage>–<lpage>e884</lpage>. DOI: <pub-id pub-id-type="doi">10.1161/CIR.0000000000000482</pub-id>
.<pub-id pub-id-type="pmid">28289069</pub-id></mixed-citation>
              </ref>
              <ref id="jah35911-bib-0021">
                <label>21</label>
                <mixed-citation publication-type="journal" id="jah35911-cit-0021"><string-name><surname>Yokoyama</surname><given-names>M</given-names></string-name>, <string-name><surname>Origasa</surname><given-names>H</given-names></string-name>, <string-name><surname>Matsuzaki</surname><given-names>M</given-names></string-name>, <string-name><surname>Matsuzawa</surname><given-names>Y</given-names></string-name>, <string-name><surname>Saito</surname><given-names>Y</given-names></string-name>, <string-name><surname>Ishikawa</surname><given-names>Y</given-names></string-name>, <string-name><surname>Oikawa</surname><given-names>S</given-names></string-name>, <string-name><surname>Sasaki</surname><given-names>J</given-names></string-name>, <string-name><surname>Hishida</surname><given-names>H</given-names></string-name>, <string-name><surname>Itakura</surname><given-names>H</given-names></string-name>, et al. <article-title>Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open‐label, blinded endpoint analysis</article-title>. <source xml:lang="en">Lancet</source>. <year>2007</year>;<volume>369</volume>:<fpage>1090</fpage>–<lpage>1098</lpage>. DOI: <pub-id pub-id-type="doi">10.1016/S0140-6736(07)60527-3</pub-id>
.<pub-id pub-id-type="pmid">17398308</pub-id></mixed-citation>
              </ref>
              <ref id="jah35911-bib-0022">
                <label>22</label>
                <mixed-citation publication-type="journal" id="jah35911-cit-0022"><collab collab-type="authors">Investigators OT</collab>
, <string-name><surname>Bosch</surname><given-names>J</given-names></string-name>, <string-name><surname>Gerstein</surname><given-names>HC</given-names></string-name>, <string-name><surname>Dagenais</surname><given-names>GR</given-names></string-name>, <string-name><surname>Diaz</surname><given-names>R</given-names></string-name>, <string-name><surname>Dyal</surname><given-names>L</given-names></string-name>, <string-name><surname>Jung</surname><given-names>H</given-names></string-name>, <string-name><surname>Maggiono</surname><given-names>AP</given-names></string-name>, <string-name><surname>Probstfield</surname><given-names>J</given-names></string-name>, <string-name><surname>Ramachandran</surname><given-names>A</given-names></string-name>, et al. <article-title>N‐3 fatty acids and cardiovascular outcomes in patients with dysglycemia</article-title>. <source xml:lang="en">N Engl J Med</source>. <year>2012</year>;<volume>367</volume>:<fpage>309</fpage>–<lpage>318</lpage>.<pub-id pub-id-type="pmid">22686415</pub-id></mixed-citation>
              </ref>
              <ref id="jah35911-bib-0023">
                <label>23</label>
                <mixed-citation publication-type="journal" id="jah35911-cit-0023"><string-name><surname>Kromhout</surname><given-names>D</given-names></string-name>, <string-name><surname>Giltay</surname><given-names>EJ</given-names></string-name>, <string-name><surname>Geleijnse</surname><given-names>JM</given-names></string-name>; <collab collab-type="authors">Alpha Omega Trial G</collab>
. <article-title>N‐3 fatty acids and cardiovascular events after myocardial infarction</article-title>. <source xml:lang="en">N Engl J Med</source>. <year>2010</year>;<volume>363</volume>:<fpage>2015</fpage>–<lpage>2026</lpage>. DOI: <pub-id pub-id-type="doi">10.1056/NEJMoa1003603</pub-id>
.<pub-id pub-id-type="pmid">20929341</pub-id></mixed-citation>
              </ref>
              <ref id="jah35911-bib-0024">
                <label>24</label>
                <mixed-citation publication-type="journal" id="jah35911-cit-0024"><string-name><surname>Albert</surname><given-names>CM</given-names></string-name>, <string-name><surname>Campos</surname><given-names>H</given-names></string-name>, <string-name><surname>Stampfer</surname><given-names>MJ</given-names></string-name>, <string-name><surname>Ridker</surname><given-names>PM</given-names></string-name>, <string-name><surname>Manson</surname><given-names>JE</given-names></string-name>, <string-name><surname>Willett</surname><given-names>WC</given-names></string-name>, <string-name><surname>Ma</surname><given-names>J</given-names></string-name>. <article-title>Blood levels of long‐chain n‐3 fatty acids and the risk of sudden death</article-title>. <source xml:lang="en">N Engl J Med</source>. <year>2002</year>;<volume>346</volume>:<fpage>1113</fpage>–<lpage>1118</lpage>. DOI: <pub-id pub-id-type="doi">10.1056/NEJMoa012918</pub-id>
.<pub-id pub-id-type="pmid">11948270</pub-id></mixed-citation>
              </ref>
              <ref id="jah35911-bib-0025">
                <label>25</label>
                <mixed-citation publication-type="journal" id="jah35911-cit-0025"><string-name><surname>Chowdhury</surname><given-names>R</given-names></string-name>, <string-name><surname>Warnakula</surname><given-names>S</given-names></string-name>, <string-name><surname>Kunutsor</surname><given-names>S</given-names></string-name>, <string-name><surname>Crowe</surname><given-names>F</given-names></string-name>, <string-name><surname>Ward</surname><given-names>HA</given-names></string-name>, <string-name><surname>Johnson</surname><given-names>L</given-names></string-name>, <string-name><surname>Franco</surname><given-names>OH</given-names></string-name>, <string-name><surname>Butterworth</surname><given-names>AS</given-names></string-name>, <string-name><surname>Forouhi</surname><given-names>NG</given-names></string-name>, <string-name><surname>Thompson</surname><given-names>SG</given-names></string-name>, et al. <article-title>Association of dietary, circulating, and supplement fatty acids with coronary risk: a systematic review and meta‐analysis</article-title>. <source xml:lang="en">Ann Intern Med</source>. <year>2014</year>;<volume>160</volume>:<fpage>398</fpage>–<lpage>406</lpage>. DOI: <pub-id pub-id-type="doi">10.7326/M13-1788</pub-id>
.<pub-id pub-id-type="pmid">24723079</pub-id></mixed-citation>
              </ref>
              <ref id="jah35911-bib-0026">
                <label>26</label>
                <mixed-citation publication-type="journal" id="jah35911-cit-0026"><string-name><surname>Aarsetoey</surname><given-names>H</given-names></string-name>, <string-name><surname>Ponitz</surname><given-names>V</given-names></string-name>, <string-name><surname>Grundt</surname><given-names>H</given-names></string-name>, <string-name><surname>Staines</surname><given-names>H</given-names></string-name>, <string-name><surname>Harris</surname><given-names>WS</given-names></string-name>, <string-name><surname>Nilsen</surname><given-names>DW</given-names></string-name>. <article-title>(n‐3) fatty acid content of red blood cells does not predict risk of future cardiovascular events following an acute coronary syndrome</article-title>. <source xml:lang="en">J Nutr</source>. <year>2009</year>;<volume>139</volume>:<fpage>507</fpage>–<lpage>513</lpage>. DOI: <pub-id pub-id-type="doi">10.3945/jn.108.096446</pub-id>
.<pub-id pub-id-type="pmid">19158216</pub-id></mixed-citation>
              </ref>
              <ref id="jah35911-bib-0027">
                <label>27</label>
                <mixed-citation publication-type="journal" id="jah35911-cit-0027"><string-name><surname>Marston</surname><given-names>NA</given-names></string-name>, <string-name><surname>Giugliano</surname><given-names>RP</given-names></string-name>, <string-name><surname>Im</surname><given-names>K</given-names></string-name>, <string-name><surname>Silverman</surname><given-names>MG</given-names></string-name>, <string-name><surname>O'Donoghue</surname><given-names>ML</given-names></string-name>, <string-name><surname>Wiviott</surname><given-names>SD</given-names></string-name>, <string-name><surname>Ference</surname><given-names>BA</given-names></string-name>, <string-name><surname>Sabatine</surname><given-names>MS</given-names></string-name>. <article-title>Association between triglyceride lowering and reduction of cardiovascular risk across multiple lipid‐lowering therapeutic classes: a systematic review and meta‐regression analysis of randomized controlled trials</article-title>. <source xml:lang="en">Circulation</source>. <year>2019</year>;<volume>140</volume>:<fpage>1308</fpage>–<lpage>1317</lpage>. DOI: <pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.119.041998</pub-id>
.<pub-id pub-id-type="pmid">31530008</pub-id></mixed-citation>
              </ref>
              <ref id="jah35911-bib-0028">
                <label>28</label>
                <mixed-citation publication-type="journal" id="jah35911-cit-0028"><string-name><surname>Mason</surname><given-names>RP</given-names></string-name>, <string-name><surname>Libby</surname><given-names>P</given-names></string-name>, <string-name><surname>Bhatt</surname><given-names>DL</given-names></string-name>. <article-title>Emerging mechanisms of cardiovascular protection for the omega‐3 fatty acid eicosapentaenoic acid</article-title>. <source xml:lang="en">Arterioscler Thromb Vasc Biol</source>. <year>2020</year>;<volume>40</volume>:<fpage>1135</fpage>–<lpage>1147</lpage>. DOI: <pub-id pub-id-type="doi">10.1161/ATVBAHA.119.313286</pub-id>
.<pub-id pub-id-type="pmid">32212849</pub-id></mixed-citation>
              </ref>
              <ref id="jah35911-bib-0029">
                <label>29</label>
                <mixed-citation publication-type="journal" id="jah35911-cit-0029"><string-name><surname>Nicholls</surname><given-names>SJ</given-names></string-name>, <string-name><surname>Lincoff</surname><given-names>AM</given-names></string-name>, <string-name><surname>Bash</surname><given-names>D</given-names></string-name>, <string-name><surname>Ballantyne</surname><given-names>CM</given-names></string-name>, <string-name><surname>Barter</surname><given-names>PJ</given-names></string-name>, <string-name><surname>Davidson</surname><given-names>MH</given-names></string-name>, <string-name><surname>Kastelein</surname><given-names>JJP</given-names></string-name>, <string-name><surname>Koenig</surname><given-names>W</given-names></string-name>, <string-name><surname>McGuire</surname><given-names>DK</given-names></string-name>, <string-name><surname>Mozaffarian</surname><given-names>D</given-names></string-name>, et al. <article-title>Assessment of omega‐3 carboxylic acids in statin‐treated patients with high levels of triglycerides and low levels of high‐density lipoprotein cholesterol: rationale and design of the STRENGTH trial</article-title>. <source xml:lang="en">Clin Cardiol</source>. <year>2018</year>;<volume>41</volume>:<fpage>1281</fpage>–<lpage>1288</lpage>. DOI: <pub-id pub-id-type="doi">10.1002/clc.23055</pub-id>
.<pub-id pub-id-type="pmid">30125052</pub-id></mixed-citation>
              </ref>
              <ref id="jah35911-bib-0030">
                <label>30</label>
                <mixed-citation publication-type="journal" id="jah35911-cit-0030"><string-name><surname>Nicholls</surname><given-names>SJ</given-names></string-name>, <string-name><surname>Lincoff</surname><given-names>AM</given-names></string-name>, <string-name><surname>Garcia</surname><given-names>M</given-names></string-name>, <string-name><surname>Bash</surname><given-names>D</given-names></string-name>, <string-name><surname>Ballantyne</surname><given-names>CM</given-names></string-name>, <string-name><surname>Barter</surname><given-names>PJ</given-names></string-name>, <string-name><surname>Davidson</surname><given-names>MH</given-names></string-name>, <string-name><surname>Kastelein</surname><given-names>JJP</given-names></string-name>, <string-name><surname>Koenig</surname><given-names>W</given-names></string-name>, <string-name><surname>McGuire</surname><given-names>DK</given-names></string-name>, et al. <article-title>Effect of High‐Dose Omega‐3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk: The STRENGTH Randomized Clinical Trial</article-title>. <source xml:lang="en">JAMA</source>. <year>2020</year>;<volume>324</volume>:<fpage>2268</fpage>–<lpage>2280</lpage>.<pub-id pub-id-type="pmid">33190147</pub-id></mixed-citation>
              </ref>
              <ref id="jah35911-bib-0031">
                <label>31</label>
                <mixed-citation publication-type="journal" id="jah35911-cit-0031"><string-name><surname>Wang</surname><given-names>C</given-names></string-name>, <string-name><surname>Harris</surname><given-names>WS</given-names></string-name>, <string-name><surname>Chung</surname><given-names>M</given-names></string-name>, <string-name><surname>Lichtenstein</surname><given-names>AH</given-names></string-name>, <string-name><surname>Balk</surname><given-names>EM</given-names></string-name>, <string-name><surname>Kupelnick</surname><given-names>B</given-names></string-name>, <string-name><surname>Jordan</surname><given-names>HS</given-names></string-name>, <string-name><surname>Lau</surname><given-names>J</given-names></string-name>. <article-title>N‐3 fatty acids from fish or fish‐oil supplements, but not alpha‐linolenic acid, benefit cardiovascular disease outcomes in primary‐ and secondary‐prevention studies: a systematic review</article-title>. <source xml:lang="en">Am J Clin Nutr</source>. <year>2006</year>;<volume>84</volume>:<fpage>5</fpage>–<lpage>17</lpage>.<pub-id pub-id-type="pmid">16825676</pub-id></mixed-citation>
              </ref>
              <ref id="jah35911-bib-0032">
                <label>32</label>
                <mixed-citation publication-type="journal" id="jah35911-cit-0032"><string-name><surname>Mente</surname><given-names>A</given-names></string-name>, <string-name><surname>de Koning</surname><given-names>L</given-names></string-name>, <string-name><surname>Shannon</surname><given-names>HS</given-names></string-name>, <string-name><surname>Anand</surname><given-names>SS</given-names></string-name>. <article-title>A systematic review of the evidence supporting a causal link between dietary factors and coronary heart disease</article-title>. <source xml:lang="en">Arch Intern Med</source>. <year>2009</year>;<volume>169</volume>:<fpage>659</fpage>–<lpage>669</lpage>. DOI: <pub-id pub-id-type="doi">10.1001/archinternmed.2009.38</pub-id>
.<pub-id pub-id-type="pmid">19364995</pub-id></mixed-citation>
              </ref>
              <ref id="jah35911-bib-0033">
                <label>33</label>
                <mixed-citation publication-type="journal" id="jah35911-cit-0033"><string-name><surname>Pan</surname><given-names>A</given-names></string-name>, <string-name><surname>Chen</surname><given-names>M</given-names></string-name>, <string-name><surname>Chowdhury</surname><given-names>R</given-names></string-name>, <string-name><surname>Wu</surname><given-names>JH</given-names></string-name>, <string-name><surname>Sun</surname><given-names>Q</given-names></string-name>, <string-name><surname>Campos</surname><given-names>H</given-names></string-name>, <string-name><surname>Mozaffarian</surname><given-names>D</given-names></string-name>, <string-name><surname>Hu</surname><given-names>FB</given-names></string-name>. <article-title>Alpha‐linolenic acid and risk of cardiovascular disease: a systematic review and meta‐analysis</article-title>. <source xml:lang="en">Am J Clin Nutr</source>. <year>2012</year>;<volume>96</volume>:<fpage>1262</fpage>–<lpage>1273</lpage>.<pub-id pub-id-type="pmid">23076616</pub-id></mixed-citation>
              </ref>
              <ref id="jah35911-bib-0034">
                <label>34</label>
                <mixed-citation publication-type="journal" id="jah35911-cit-0034"><string-name><surname>Brouwer</surname><given-names>IA</given-names></string-name>, <string-name><surname>Raitt</surname><given-names>MH</given-names></string-name>, <string-name><surname>Dullemeijer</surname><given-names>C</given-names></string-name>, <string-name><surname>Kraemer</surname><given-names>DF</given-names></string-name>, <string-name><surname>Zock</surname><given-names>PL</given-names></string-name>, <string-name><surname>Morris</surname><given-names>C</given-names></string-name>, <string-name><surname>Katan</surname><given-names>MB</given-names></string-name>, <string-name><surname>Connor</surname><given-names>WE</given-names></string-name>, <string-name><surname>Camm</surname><given-names>JA</given-names></string-name>, <string-name><surname>Schouten</surname><given-names>EG</given-names></string-name>, et al. <article-title>Effect of fish oil on ventricular tachyarrhythmia in three studies in patients with implantable cardioverter defibrillators</article-title>. <source xml:lang="en">Eur Heart J</source>. <year>2009</year>;<volume>30</volume>:<fpage>820</fpage>–<lpage>826</lpage>. DOI: <pub-id pub-id-type="doi">10.1093/eurheartj/ehp003</pub-id>
.<pub-id pub-id-type="pmid">19196720</pub-id></mixed-citation>
              </ref>
              <ref id="jah35911-bib-0035">
                <label>35</label>
                <mixed-citation publication-type="journal" id="jah35911-cit-0035"><string-name><surname>Siscovick</surname><given-names>DS</given-names></string-name>, <string-name><surname>Raghunathan</surname><given-names>TE</given-names></string-name>, <string-name><surname>King</surname><given-names>I</given-names></string-name>, <string-name><surname>Weinmann</surname><given-names>S</given-names></string-name>, <string-name><surname>Wicklund</surname><given-names>KG</given-names></string-name>, <string-name><surname>Albright</surname><given-names>J</given-names></string-name>, <string-name><surname>Bovbjerg</surname><given-names>V</given-names></string-name>, <string-name><surname>Arbogast</surname><given-names>P</given-names></string-name>, <string-name><surname>Smith</surname><given-names>H</given-names></string-name>, <string-name><surname>Kushi</surname><given-names>LH</given-names></string-name>, et al. <article-title>Dietary intake and cell membrane levels of long‐chain n‐3 polyunsaturated fatty acids and the risk of primary cardiac arrest</article-title>. <source xml:lang="en">JAMA</source>. <year>1995</year>;<volume>274</volume>:<fpage>1363</fpage>–<lpage>1367</lpage>. DOI: <pub-id pub-id-type="doi">10.1001/jama.1995.03530170043030</pub-id>
.<pub-id pub-id-type="pmid">7563561</pub-id></mixed-citation>
              </ref>
              <ref id="jah35911-bib-0036">
                <label>36</label>
                <mixed-citation publication-type="journal" id="jah35911-cit-0036"><string-name><surname>Rimm</surname><given-names>EB</given-names></string-name>, <string-name><surname>Appel</surname><given-names>LJ</given-names></string-name>, <string-name><surname>Chiuve</surname><given-names>SE</given-names></string-name>, <string-name><surname>Djousse</surname><given-names>L</given-names></string-name>, <string-name><surname>Engler</surname><given-names>MB</given-names></string-name>, <string-name><surname>Kris‐Etherton</surname><given-names>PM</given-names></string-name>, <string-name><surname>Mozaffarian</surname><given-names>D</given-names></string-name>, <string-name><surname>Siscovick</surname><given-names>DS</given-names></string-name>, <string-name><surname>Lichtenstein</surname><given-names>AH</given-names></string-name>; <collab collab-type="authors">American Heart Association Nutrition Committee of the Council on L</collab>
. <article-title>Seafood long‐chain n‐3 polyunsaturated fatty acids and cardiovascular disease: a science advisory from the American Heart Association</article-title>. <source xml:lang="en">Circulation</source>. <year>2018</year>;<volume>138</volume>:<fpage>e35</fpage>–<lpage>e47</lpage>. DOI: <pub-id pub-id-type="doi">10.1161/CIR.0000000000000574</pub-id>
.<pub-id pub-id-type="pmid">29773586</pub-id></mixed-citation>
              </ref>
              <ref id="jah35911-bib-0037">
                <label>37</label>
                <mixed-citation publication-type="journal" id="jah35911-cit-0037"><string-name><surname>Raitt</surname><given-names>MH</given-names></string-name>, <string-name><surname>Connor</surname><given-names>WE</given-names></string-name>, <string-name><surname>Morris</surname><given-names>C</given-names></string-name>, <string-name><surname>Kron</surname><given-names>J</given-names></string-name>, <string-name><surname>Halperin</surname><given-names>B</given-names></string-name>, <string-name><surname>Chugh</surname><given-names>SS</given-names></string-name>, <string-name><surname>McClelland</surname><given-names>J</given-names></string-name>, <string-name><surname>Cook</surname><given-names>J</given-names></string-name>, <string-name><surname>MacMurdy</surname><given-names>K</given-names></string-name>, <string-name><surname>Swenson</surname><given-names>R</given-names></string-name>, et al. <article-title>Fish oil supplementation and risk of ventricular tachycardia and ventricular fibrillation in patients with implantable defibrillators: a randomized controlled trial</article-title>. <source xml:lang="en">JAMA</source>. <year>2005</year>;<volume>293</volume>:<fpage>2884</fpage>–<lpage>2891</lpage>. DOI: <pub-id pub-id-type="doi">10.1001/jama.293.23.2884</pub-id>
.<pub-id pub-id-type="pmid">15956633</pub-id></mixed-citation>
              </ref>
              <ref id="jah35911-bib-0038">
                <label>38</label>
                <mixed-citation publication-type="journal" id="jah35911-cit-0038"><string-name><surname>Billman</surname><given-names>GE</given-names></string-name>, <string-name><surname>Carnes</surname><given-names>CA</given-names></string-name>, <string-name><surname>Adamson</surname><given-names>PB</given-names></string-name>, <string-name><surname>Vanoli</surname><given-names>E</given-names></string-name>, <string-name><surname>Schwartz</surname><given-names>PJ</given-names></string-name>. <article-title>Dietary omega‐3 fatty acids and susceptibility to ventricular fibrillation: lack of protection and a proarrhythmic effect</article-title>. <source xml:lang="en">Circ Arrhythm Electrophysiol</source>. <year>2012</year>;<volume>5</volume>:<fpage>553</fpage>–<lpage>560</lpage>. DOI: <pub-id pub-id-type="doi">10.1161/CIRCEP.111.966739</pub-id>
.<pub-id pub-id-type="pmid">22333345</pub-id></mixed-citation>
              </ref>
              <ref id="jah35911-bib-0039">
                <label>39</label>
                <mixed-citation publication-type="journal" id="jah35911-cit-0039"><string-name><surname>Arab</surname><given-names>L</given-names></string-name>. <article-title>Biomarkers of fat and fatty acid intake</article-title>. <source xml:lang="en">J Nutr</source>. <year>2003</year>;<volume>133</volume>(<issue>suppl 3</issue>):<fpage>925S</fpage>–<lpage>932S</lpage>. DOI: <pub-id pub-id-type="doi">10.1093/jn/133.3.925S</pub-id>
.<pub-id pub-id-type="pmid">12612178</pub-id></mixed-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
